

Neurotrophic keratopathy

Dua, Harminder S.; Said, Dalia G.; Messmer, Elisabeth M.; Rolando, Maurizio; Benitez-Del-Castillo, Jose M.; Hossain, Parwez N.; Shortt, Alex J.; Gerling, Gerd; Nubile, Mario; Figueiredo, Francisco C.; Rauz, Saaeha; Mastropasqua, Leonardo; Rama, Paolo; Baudouin, Christophe

DOI:

[10.1016/j.preteyeres.2018.04.003](https://doi.org/10.1016/j.preteyeres.2018.04.003)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Dua, HS, Said, DG, Messmer, EM, Rolando, M, Benitez-Del-Castillo, JM, Hossain, PN, Shortt, AJ, Gerling, G, Nubile, M, Figueiredo, FC, Rauz, S, Mastropasqua, L, Rama, P & Baudouin, C 2018, 'Neurotrophic keratopathy', *Progress in Retinal and Eye Research*. <https://doi.org/10.1016/j.preteyeres.2018.04.003>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked for eligibility: 18/05/2018
[10.1016/j.preteyeres.2018.04.003](https://doi.org/10.1016/j.preteyeres.2018.04.003)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Title: Neuropathic Keratopathy

Contents:

1. Introduction	06
2. History	07
3. Nomenclature	08
4. Definition	09
5. Anatomy and Physiology of corneal nerves	11
5.1 Anatomy	11
5.2 Physiology	14
6. Incidence and Prevalence	17
7. Aetiology and Pathogenesis of Neurotrophic Keratopathy	19
7.1 Aetiology	19
7.2 Pathogenesis	19
7.3 Natural History of Neurotrophic Keratopathy	24
8. Clinical Presentation and Classification	26
8.1 Clinical Features	26
8.2 Classification	28
9. Diagnosis and Differential Diagnosis	30
9.1 Ocular symptoms	30
9.2 Clinical history	31
9.3 Examination	31
9.4 Vital staining	33
9.5 Diagnostic tests	33
9.6 Differential Diagnosis	36
10. Management	37
10.1 Medical Management	37
10.2 Non-surgical Intervention	44
10.3 Surgical Intervention	47
12. Future Directions	56
13. Funding support	58
14. Acknowledgement	58
15. References	58

Abbreviations

AMT	Amniotic membrane transplant
ASOCT	Anterior Segment Optical Coherence Tomography
BAK	Benzalkonium chloride
BNGA	Belmonte non-contact gas aesthesiometer
CGRP	Calcitonin gene-related peptide
IVCM	In Vivo Confocal Microscopy
LC	Langerhans cells
MMP	Matrix metalloproteases
NGF	Nerve Growth Factor
NK	Neurotrophic Keratopathy
PED	Persistent epithelial defect
SCG	Superior Cervical Ganglion
SPK	Superficial punctate keratitis
TRP	Transient Receptor Potential
VEGF	Vascular Endothelial Growth Factor

Abstract

Neurotrophic Keratopathy (NK) refers to a condition where corneal epitheliopathy leading to frank epithelial defect with or without stromal ulceration (melting) is associated with reduced or absent corneal sensations. Sensory nerves serve nociceptor and trophic functions, which can be affected independently or simultaneously. Loss of trophic function and consequent epithelial breakdown exposes the stroma making it susceptible to enzymatic degradation. Nerve pathology can range from attrition to aberrant re-generation with corresponding symptoms from anaesthesia to hyperaesthesia/allodynia. Many systemic and ocular conditions, including surgery and preserved medications can lead to NK. NK can be mild (epithelium and tear film changes), moderate (non-healing epithelial defect) or severe (stromal melting and perforation). Moderate and severe NK can profoundly affect vision and adversely impact on the quality of life. Medical management with lubricating agents from artificial tears to serum/plasma drops, anti-inflammatory agents, antibiotics and anti-proteases all provide non-specific relief, which may be temporary. Contact lenses, punctal plugs, lid closure with botulinum toxin and surgical interventions like tarsorrhaphy, conjunctival flaps and amniotic membrane provide greater success but often at the cost of obscuring sight. Corneal surgery in a dry ocular surface with reduced sensation is at high risk of failure. The recent advent of biologicals such as biopolymers mimicking heparan sulfate; coenzyme Q10 and antisense oligonucleotide that suppress connexin 43 expression, all offer promise. Recombinant nerve growth factor (cenegermin), recently approved for human use targets the nerve pathology and has the potential of addressing the underlying deficit and becoming a specific therapy for NK.

24 **Key Words:**

- 25 1. Keratitis
26 2. Neurotrophic Keratopathy
27 3. Trigeminal Neve diseases
28 4. Matrix Regenerating agents
29 5. Nerve growth factor

30

31 1. Introduction

32

33 The ocular surface is a continuous epithelium and underlying stroma extending from the
34 muco-cutaneous junction at the eye lid margin to the corneal surface. It is a specialised system
35 that closely interacts with associated adnexal structures, lacrimal glands and eyelids (known as
36 the lacrimal functional unit), and via cross-talk with the neural, endocrine, vascular, and immune
37 regulatory systems (Gipson, 2007). Aragona and Rolando described the ocular surface unit as a
38 dynamic complex that includes the eye lids, tear film, conjunctiva and cornea functioning as a
39 single unit, where one reflects and influences the others (Aragona and Rolando, 2013). It
40 represents the interface between the external environment and the eye. Its key function is to
41 guarantee a clear optical surface to direct light to the retina, a neural tissue inside the eye that
42 signals to the brain for visual recognition. It also provides protection for the inner structures of
43 the eye. To do this it must be able to quickly adapt to the changing conditions of the environment
44 or pathologic stresses, and generate functional and anatomical responses to maintain
45 homeostasis. An integration among neural, cellular, immune, and tear film related responses is
46 the basis of its ability to react and adapt quickly. Proper function of the tear film, lids and
47 conjunctiva and their neural, hormonal, immune connections are all essential in maintenance of
48 the cornea (Rolando and Zierhut, 2001). The inability to adapt or failure of one or more of its
49 components gives rise to vicious cycles of inflammation and damage, which if not promptly
50 contained will initiate and maintain ocular surface disease. Ocular surface disease is therefore the
51 result of a progressive cascade of events involving simultaneously or sequentially, one or more
52 of the different components of the system that is unable to compensate, respond and heal
53 (Aragona and Rolando, 2013; Baudouin et al., 2013).

54 The avascular, squamous corneal epithelium is innervated by a dense mesh of sensory
55 processes derived from the ophthalmic branch of the trigeminal nerve (Muller et al., 2003).
56 These nerve endings are responsible for nociception, cold and pressure sensation. The 7000
57 nerve receptors per square mm of the cornea and their fibres are involved in protecting the
58 cornea from damage by modulating the blink response, stimulating the production of tears and
59 maintaining the cornea in a healthy state through the production of trophic factors (You et al.,
60 2000). Nerve malfunction is the hallmark of neurotrophic keratopathy (NK). Corneal epithelial
61 cells constantly turnover by cell desquamation at the surface, cell regeneration at the limbus and
62 centripetal sliding and migration from the limbus. When the epithelium is injured, cells
63 surrounding the wound migrate onto the wound bed to re-establish cover. This repair requires a
64 controlled and collaborative system of communication between epithelial and neuronal cells to
65 facilitate re-synthesis of the damaged matrix, cell migration and restoration of architecture
66 (Zieske and Gipson, 1986). If epithelial healing is impaired, the exposed stroma becomes
67 vulnerable to enzymatic degradation, melting and eventually perforation; features that represent
68 severe NK (Fini et al., 1998).

69

70 **2. Brief History of Neurotrophic Keratopathy**

71

72 That transection of the trigeminal nerve can lead to degenerative changes in the cornea was
73 first described by Magendie in 1824 (Magendie, 1824), and Middlemore in 1835 recognized that
74 the cornea was one of the most sensitive structures in the body (Middlemore, 1835). Changes of
75 a destructive nature were not confined to the cornea alone; similar changes were noted in the skin
76 corresponding to the area supplied by the nerve transected or damaged. The skin changes

77 included a sensory deficit, vasodilation, swelling and the development of trophic ulcers also
 78 described in the past as “sluggish” ulcers (Dubler, 1884). The term ‘trophic’ relates to nutrition.
 79 A trophic nerve would be one that is associated with nutrition or regulates the metabolism of
 80 cells. It was initially considered that the Vth cranial nerve carried trophic fibres (sympathetic)
 81 but this has never been proven. Besides the trophic hypothesis, various other hypotheses were
 82 put forth to explain the corneal changes that follow trigeminal nerve damage: irritative nerve
 83 action wherein the damaged corneal nerves generate harmful stimuli; vascular or vasomotor
 84 disturbance related to loss of control of limbal and conjunctival vessels; trauma, which is of real
 85 concern as wounds heal slowly and an eye that is protected from trauma (eye closure) suffers
 86 less; desiccation and dehydration; infection; consequential cell damage and abnormal cell
 87 metabolism. Of these, the hypothesis of altered cell metabolism is the most popular and most
 88 likely. This implies that there is a “lack of normal peripheral antidromic activity of sensory
 89 nerves” (normally an impulse travels from the site of origin in the soma along the axon towards
 90 the central neuron – orthodromic. Movement in the opposite direction is antidromic). This leads
 91 to the accumulation of metabolites which in turn cause tissue swelling, loss of vitality and
 92 desquamation with the formation of a trophic ulcer. The term used to describe this condition was
 93 neuroparalytic keratitis (Klein, 1943).

94

95 3. Nomenclature

96

97 Various terms are used to describe corneal nerve related pathology. These are listed in table
 98 1. The nomenclature is based on the major clinical presentation of an epithelial defect (non-
 99 healing, slow-healing or persistent) and the underlying nerve pathology, which has a common
 100 acronym of ‘NK’ for neuroparalytic, neuropathic or neurotrophic keratitis/keratopathy. The

terms are used interchangeably and have the potential to cause confusion. The paper titled ‘Neurotrophic Keratitis’ from the Cambridge Ophthalmological symposium (Bonini et al., 2003) begins with the word ‘Neurotrophic keratopathy’ highlighting the inconsistency and the lack of a definitive term being assigned to the condition. ‘Keratitis’ is probably not the correct term to use even though inflammation is often associated with the pathogenesis or clinical presentation of the condition. The term ‘Neurotrophic Keratopathy’ with the acronym (NK) would be more appropriate as it encompasses the underlying nerve problem, the trophic effect on the cornea of nerve disease, both hypoaesthesia and hyper-excitability states, and does not place emphasis on ‘inflammation’, which is not the primary driver of the condition. The term ‘Persistent epithelial defect’ (or its variations) though a good clinical descriptor, can be associated with a variety of non-nerve related conditions. Hence it is more appropriate as a clinical sign than the name of a disease. We propose that ‘Neurotrophic keratopathy’ be used as the definitive term to describe the condition.

114

115 **4. Definition**

116

117 The definition of Neurotrophic keratopathy (NK) has remained consistent over the last
 118 couple of decades. At the Cambridge Ophthalmological Symposium in 2003 (Bonini et al.,
 119 2003), the following definition was used: “Neurotrophic keratopathy (NK) is a degenerative
 120 corneal disease induced by an impairment of trigeminal nerve. Impairment or loss of corneal
 121 sensory innervation is responsible for corneal epithelial defects, ulcer, and perforation.” The
 122 American Academy of Ophthalmology published the following definition in 2008:
 123 “Neurotrophic keratopathy (NK) is a degenerative disease of the corneal epithelium resulting

124 from impaired corneal innervation. A reduction in corneal sensitivity or complete corneal
125 anesthesia is the hallmark of this disease and is responsible for producing epithelial keratopathy,
126 ulceration and perforation (Wells and Michelson, 2008).

127 Two recent definitions published on line by very reputable entities are presented below.
128 The first one by Eye Wiki, a product of the American Academy of Ophthalmology, states that
129 “Neurotrophic Keratitis (NK) is a corneal degenerative disease characterized by a reduction or
130 absence of corneal sensitivity. In NK, corneal innervation by the trigeminal nerve is impaired”
131 (Rabiolo and Woodward, 2017).” The other published on the Medscape is similar though more
132 elaborate “Neurotrophic keratopathy (NK) is a degenerative disease characterized by decreased
133 corneal sensitivity and poor corneal healing. This disorder leaves the cornea susceptible to injury
134 and decreases reflex tearing. Epithelial breakdown can lead to ulceration, infection, melting, and
135 perforation secondary to poor healing” (Graham, 2016).

136 All definitions of NK describe it as a “degenerative disease” and all include “impaired
137 corneal innervation” as the underlying pathology. The emphasis is on “sensory nerves or corneal
138 sensation”. Recent studies have demonstrated the role of sympathetic innervation in corneal
139 pathology (Yun et al., 2016), and the occurrence of corneal nerve hyper or aberrant regeneration,
140 which is quite distinct from attrition or extinction of nerves in the sub-basal plexus (Al-Aqaba et
141 al., 2011b; Al-Aqaba et al., 2012). The role of nerve sprouting and regeneration, though not
142 resembling normal anatomy, is unclear but difficult to ignore. In dry eye disease nerve loss
143 followed by nerve regeneration consequent to therapy has been described (Benitez del Castillo et
144 al., 2004; Iaccheri et al., 2017; Tuisku et al., 2008; Zhang et al., 2005). When regeneration is a
145 component of the pathophysiology, inclusion of the term ‘degenerative disease’ in the definition
146 may introduce a contradiction. Moreover, the underlying conditions can have inflammation,

147 trauma, congenital anomalies and others as the predominant manifestation. It has also been
 148 shown that partial or total sensory loss is compatible with relatively healthy corneal epithelium
 149 (Dhillon et al., 2016), though NK when clinically manifest is associated with corneal
 150 hypoaesthesia or anaesthesia. With the above points in mind we propose the following definition:
 151 *“Neurotrophic keratopathy is a disease related to alterations in corneal nerves leading to*
 152 *impairment in sensory and trophic function with consequent breakdown of the corneal*
 153 *epithelium, affecting health and integrity of the tear film, epithelium and stroma”*. Clinically this
 154 implies that NK is the likely diagnosis in the presence of an epithelial defect that does not heal or
 155 heals and breaks down repeatedly (changing shape and size of epithelial defect) in the presence
 156 of reduced or altered corneal trophic function and sensitivity.

157

158 5. Anatomy and Physiology of Corneal Nerves

159 5.1 Anatomy

160 The cornea is arguably the most sensitive structure in the human body. It is 100 times
 161 more sensitive than the conjunctiva (Wells and Michelson, 2008), 40 times more than dental pulp
 162 and over 400 times more than the skin (Bonini et al., 2003).

163 Corneal innervation is predominantly sensory, from the ophthalmic division of the
 164 Trigeminal (V cranial) nerve ([Fig. 1](#)). 1.5% (200 to 450 neurons depending on species) of the
 165 trigeminal ganglion neurons serve the cornea (Felipe et al., 1999; Launay et al., 2015; Marfurt et
 166 al., 1989). Each neuron can support hundreds to thousands of nerve endings in the cornea
 167 (LaVail et al., 1993; Marfurt et al., 1989; Morgan et al., 1978). The nasociliary branch of the

ophthalmic division of the trigeminal nerve enters the orbit through the superior orbital fissure and is the main nerve covering the ocular surface. Two or three long ciliary nerves and a communicating branch to the ciliary ganglion arise from the nasociliary nerve before it terminates as the infra-trochlear and nasal branches (other branches are the anterior and posterior ethmoidal nerves). Six short ciliary nerves arise from the ciliary ganglion and together with the long ciliary nerves enter the suprachoroidal space by penetrating the sclera around the optic nerve. They pass anteriorly, supply the iris and ciliary body and terminate in the peri-corneal (limbal) plexus. The limbal plexus thus has both sensory and autonomic nerves and is predominantly vasomotor in function (Marfurt et al., 2010).

A mixture of sensory and autonomic nerves pass through the limbus and enter the cornea in the middle third of the stroma in a series of large, radially-oriented nerve bundles and run forward and anteriorly in a radial fashion toward the central area, giving rise to branches that innervate the anterior and mid-stroma. The posterior stroma seems to lack innervation though some investigators have noticed a sparse innervation of the corneal endothelium (Leon-Feliu et al., 1978; ten Tusscher et al., 1988; Wolter, 1957). There is a loose sub Bowman's plexus of nerves from where fibres penetrate the Bowman's zone, predominantly in the mid periphery of the cornea and emerge in the sub-basal (epithelium) plane where they end in single or multiple bulb-like structures which probably represent the termination and folding of the nerve sheath (Al-Aqaba et al., 2010). From this point numerous neurites emerge and spread across the surface of the cornea, in the sub-basal plane, dividing dichotomously and re-anastomosing to form the sub-basal plexus. The neurites are generally oriented such that they converge to an area between the upper two thirds and the lower one third where they form a distinct whorl pattern (Al-Aqaba et al., 2010; Patel and McGhee, 2009). Terminal branches from the sub-basal plexus pass

191 anteriorly into the epithelial cell layers, terminating within or in between epithelial cells (Stepp et
 192 al., 2017). A small population of axons terminates in the stroma, while others form a close
 193 anatomical relationship with stromal keratocytes and macrophages (Muller et al., 1996; Seyed-
 194 Razavi et al., 2014).

195 Autonomic innervation consists essentially of sympathetic nerves from the superior
 196 cervical ganglion (SCG). The SCG is located close to the internal carotid artery at the level of the
 197 2nd and 3rd cervical vertebrae. It receives preganglionic fibres from neurons located at the level of
 198 the 1st and 2nd thoracic spinal nerves. Postganglionic (postsynaptic) fibres from the SCG ascend
 199 in the carotid plexus around the internal carotid artery. Fibres destined for the eye leave the
 200 carotid plexus in the cavernous sinus and enter the orbit through the superior orbital fissure as
 201 the sympathetic root of the ciliary ganglion. Some fibres directly merge with the long ciliary
 202 nerves and others pass through the ciliary ganglion, without synapse, to emerge in the short
 203 ciliary nerves. Primates including humans have little sympathetic nerve supply to the cornea
 204 (Ehinger, 1971; Sugiura and Yamaga, 1968; Toivanen et al., 1987) compared to rabbits and cats
 205 where they constitute approximately 15% of the total corneal innervation (Marfurt and Ellis,
 206 1993). Rat and cat corneas also receive parasympathetic fibres from the ciliary ganglion (Marfurt
 207 et al., 1998; Morgan et al., 1987; Tervo et al., 1979). However, this kind of innervation has not
 208 been confirmed in humans. All corneal sensory nerves derive from finely myelinated (A- δ) and
 209 unmyelinated (C) axons determined by the size and presence of myelin sheaths in the axon
 210 (Felipe et al., 1999). In the human cornea, central stromal axons are unmyelinated and run in the
 211 anterior stroma as large bundles parallel to collagen bundles. Most of the axons in these bundles
 212 are about 0.5 μ m in diameter. However, few may be as large as 2.5 μ m (Muller et al., 1996;
 213 Muller et al., 1997). On the other hand, more than 70% of the axons in rabbit corneas are

unmyelinated (Beuerman et al., 1983). The rest are finely myelinated axons that lose their myelin sheath within 1 mm after penetrating the cornea (Lim and Ruskell, 1978; Rozsa and Beuerman, 1982; Zander and Weddell, 1951). Myelinated axons are present in the central cornea in some mammals (Rodger, 1950; Whitear, 1960). As soon as they enter the corneal stroma, the nerve bundles lose their perineurium and continue as elongated structures running between the collagen lamellae.

220

221 5.2 *Physiology*

The physiology of corneal nerves is complex. Aspects relevant to NK are described and included herein. Electrophysiological examinations have revealed the existence of different functional types of ocular sensory neurons, including polymodal nociceptor neurons, cold thermoreceptor neurons, and selective mechano-nociceptor neurons (Belmonte et al., 2004a; Belmonte et al., 2004b).

The majority of the sensory nerve fibres innervating the cornea are polymodal nociceptors which are activated with near-noxious or noxious mechanical energy, heat, chemical irritants, endogenous chemical mediators released by damaged corneal tissue, and by inflammatory cells (Belmonte et al., 1991; Belmonte and Giraldez, 1981; Gallar et al., 1993; MacIver and Tanelian, 1993). When the stimulus causes tissue injury severe enough to trigger local inflammation, their threshold for activation decreases, and the impulse discharge evoked by suprathreshold stimulation increases. So called “sensitization” develops and may be associated with allodynia (pain evoked by innocuous stimuli), hyperalgesia (enhanced pain in response to noxious stimuli) and spontaneous pain (Stapleton et al., 2013). Reflex tear secretion caused by corneal stimulation seems to be chiefly due to activation of corneal polymodal nociceptors

(Acosta, Peral, 2004). The transient receptor potential (TRP) cation channels subfamily V member 1 (TRPV1) plays an important role in sensory transduction in polymodal nociceptors. It is expressed in intraepithelial nerve terminal endings in the corneal epithelium (Alamri et al., 2015; Guo et al., 1999; Murata and Masuko, 2006) and is activated by capsaicin, low pH, noxious heat and hyperosmolarity (Caterina et al., 1997; Davis et al., 2000; Straub, 2014). Acid-sensing ion channels (ASICs) and TRP cation channel subfamily A member 1 (TRPA1) also appear to contribute to chemical sensitivity of corneal polymodal nociceptors (Bandell et al., 2004; Bautista et al., 2013; Callejo et al., 2015).

The neuropeptides contained in some polymodal receptors (substance P and calcitonin gen-related peptide – CGRP) maintain corneal homeostasis and integrity by promoting corneal epithelial cell proliferation, migration, adhesion and differentiation (Garcia-Hirschfeld et al., 1994; Reid et al., 1993; Tran et al., 2000). Corneal epithelial cells in turn, release soluble factors (e.g. NGF and GDNF) that promote neurite extension and survival (Chan and Haschke, 1981; Lambiase et al., 2000). Furthermore, the lacrimal gland provides growth factors and nutrients and in turn, its function is influenced by sensory nerves. About 20-30% of peripheral axons innervating the cornea are selective mechano-nociceptors, which respond only to mechanical stimuli at an order of magnitude close to that required for corneal epithelial damage (Belmonte et al., 1991; MacIver and Tanelian, 1993). These mechano-nociceptors are probably responsible for the acute, sharp pain sensation induced by touching or scratching the corneal surface. Piezo2, a newly identified mechanically sensitive ion channel is present in about 30% of corneal sensory neurons in the trigeminal ganglion, but has not been described yet in the intraepithelial nerve terminals (Alamri et al., 2015; Bron et al., 2014). Cold thermoreceptors represent 10-15% of the total population of corneal sensory neurons (Belmonte et al., 2017). They change their activity

with both cooling and heating as well as with changes in osmolarity (Carr et al., 2003; Gallar et al., 1993; Parra et al., 2014; Quallo et al., 2015). Their activity is modulated by inflammation, which reduces their impulse activity as well as by peripheral injury that increases firing frequency (Acosta et al., 2013). The TRP subfamily member M8 is a cation channel that is important for cold sensation. It is activated by cooling, menthol, and osmolality values greater than 340 mOsm. (McKemy et al., 2002; Parra et al., 2010; Peier et al., 2002; Quallo et al., 2015). In the rabbit cornea, specific populations of c-fibers exist which are stimulated by acetylcholine possibly acting via a neuronal nicotinic receptor (Tanelian, 1991).

Nerve growth factor (NGF), epidermal growth factor (EGF), glial derived neurotrophic factor (GDNF) as well as brain derived neurotrophic factor (BDNF) are the main agents of an epithelial-nerve cross talk which plays a fundamental role in corneal wellbeing and healing (Muller et al., 2003). NGF, GDNF, their receptors TrkA and GFRa-1, as well as BDNF may also play an important role in maintaining corneal epithelial stem cells in the limbus (Qi et al., 2007). In addition, NGF seems to facilitate innervation of perivascular nerves to regulate blood flow in corneal neovascularization (Matsuyama et al., 2017). Recent evidence indicates, that significant and complex interactions exist between the nervous and immune system. Primary sensory neurons seem to be involved in maintaining the cornea's immune privilege (Belmonte et al., 2017). Moreover, peptidergic polymodal nociceptor terminals with their sensory neuropeptides substance P and CGRP contribute to the inflammatory response following tissue injury (neurogenic inflammation) (Belmonte et al., 2004a): CGRP has immunosuppressive effects, while substance P acts as a potent pro-inflammatory neuropeptide (Micera et al., 2006; Reynier-Rebuffel et al., 1994). Fractalkine (FKN, CX3XL1), produced by primary sensory neurons, plays an important role in the maintenance of corneal well-being, and disturbances in FKN/CX3CR1-

283 signalling may also result in corneal inflammation (Clark, 2014). NGF is a constitutive molecule
 284 present and produced in normal human corneas and important for the development and
 285 maintenance of peripheral sensory neurons. NGF and/or NGF-receptors TrkA and p75NTR are
 286 expressed in many corneal tissues including epithelium, endothelium, keratocytes and nerves, as
 287 well as by bone marrow (BM) derived cells present in the cornea (Lambiase et al., 2000; Sarkar
 288 et al., 2013). Tear NGF is increased after both photorefractive keratectomy and laser in situ
 289 keratomileusis (Lee et al., 2005). In addition, some semaphorins such as Sema7A and VEGF-A
 290 act as neurotrophic factors in the cornea and are able to influence inflammatory events (Li et al.,
 291 2011; Namavari et al., 2012; Takamatsu and Kumanogoh, 2012). T-cell-dependent inflammation
 292 involving IL-17, neutrophils, platelets, and VEGF-A seems to promote corneal nerve
 293 regeneration (Li et al., 2011; Namavari et al., 2012; Takamatsu and Kumanogoh, 2012).

294 In a healthy eye, bidirectional communication between nerves and the immune system
 295 forms a negative feedback loop that keeps both systems in check (Belmonte et al., 2017). Minor
 296 insults to the ocular surface are rapidly healed within a continuous trophic environment
 297 maintained by corneal innervation and the tear film (Mathers, 2000; Stern et al., 1998).

298

299 **6. Incidence and prevalence**

300

301 To determine the prevalence and incidence of a disease it is necessary to first agree upon a
 302 definition (DEWS report 2007). With regard to NK, as highlighted above, the definition has not
 303 changed for more than 15 years. In the context of the prevailing definition, NK has been
 304 classified as a rare/orphan disease (ORPHA137596) affecting 5 individuals or fewer in 10,000.

305 NK requires a fresh and joined approach by all stakeholders to enable effective treatment in the
 306 context of all options available.

307 There is a paucity of information in the literature regarding the prevalence and incidence of
 308 NK. The best evidence available (Sacchetti and Lambiase, 2014) is based on extrapolation from
 309 the two most common conditions associated with NK, which are herpetic keratitis (incidence of
 310 1.22/10,000) and post-surgical nerve damage (incidence of 0.02/10,000); as being below
 311 1.6/10,000. More specifically, NK develops in an average of 6% of herpetic keratitis cases,
 312 which has a prevalence of 149/100,000 (Labetoulle et al., 2005) and in 12.8% of herpes zoster
 313 keratitis cases, which has a prevalence of 26/100,000 (Dworkin et al., 2007). Other than herpetic
 314 keratitis, the most common cause of NK is neurosurgical intervention to treat trigeminal
 315 neuralgia that damages the trigeminal nerve (post-surgical incidence of 2.8%), which has a
 316 prevalence of 1.5/10,000, and an estimated prevalence of NK after neurosurgical procedure of
 317 0.02/10,000 (Bhatti and Patel, 2005). Unfortunately, no epidemiological data can be found in the
 318 literature for a number of other common conditions known to cause NK such as chemical burns,
 319 diabetes, contact lenses and less frequent causes such as space occupying intracranial masses,
 320 multiple sclerosis and leprosy.

321 Geerling et al. (unpublished observations, 2017) in a retrospective case series from a
 322 subspecialist -corneal clinic in Germany identified 38 eyes of 35 patients (17 males and 18
 323 females with a mean age of 67 years) with NK over a two year period (2015-2016). They
 324 searched for patients, who were treated with autologous serum eye drops, amniotic membrane
 325 transplantation, emergency corneal grafting or a combination thereof (commonly employed
 326 treatments for moderate to severe NK). 40.6% of emergency corneal grafts (13 out of 32), 15%

of amniotic membrane transplantations (28 out of 187) and 17.9% of autologous serum treatments (7 out of 39) were related to NK.

Although dry eyes are a feature of NK, dry eye disease and NK are different clinical entities. Some convergence is seen however, when laser refractive surgery is considered as a cause of neuropathic dry eye (Chao et al., 2014). The incidence of neuropathic dry eye following laser in-situ keratomileusis is estimated to be between 2 to 5% of Caucasian patients, rising to around 28% in Asians (Albietz et al., 2005; Azuma et al., 2014).

7. Aetiology and Pathogenesis of Neurotrophic Keratopathy

7.1 Etiology of Neurotrophic Keratopathy

Any persistent alteration of the corneal sensory innervation interfering with the function of the post-ganglionic fibres can cause NK (Sacchetti and Lambiase, 2014). (Fibres projecting from cortical/spinal nuclei to the trigeminal ganglion are pre-ganglionic and those projecting from the ganglion to the ocular surface are post-ganglionic). The common causes of severe NK are corneal herpes infections, ocular surface thermal and chemical burns, contact lens misuse and cranial neurosurgery. A number of events and ocular and systemic conditions can chronically affect the functioning of corneal nerves inducing NK. Unpublished observations [Figueiredo G, Baylis O, Lako M, Figueiredo FC] -from a prospective phase II clinical trial in the UK on treatment of unilateral ocular surface burns related total limbal stem cell deficiency (LSCD) with *ex vivo* expanded autologous limbal stem cell transplantation demonstrated that that all 23 patients studied also had NK in the affected eye. The mean age of patients was 44.7 years (range 24-81, SD 14.19). The mean Cochet-Bonnet aesthesiometry measurement was 9.13 (range

0-30, SD 9.73) in the LSCD/NK eyes and 59.13 (range 50-60, SD 2.881) in the fellow normal eyes. The difference between the LSCD/NK and fellow eyes was statistically significant ($p < 0.0001$, Wilcoxon rank test). A summary of the common causes of ocular surface nerve damage is given in table 2.

353

7.2 Pathogenesis of NK

In animal models, ocular nerve injury causes swelling of the squamous epithelial cells, loss of cell surface microvilli, abnormal basement production, acceleration of sloughing and loss of cells in to the tears, with epithelial thinning and breakdown ([Mishima, 1957](#); Alper, 1975; Beuerman and Schimmelpfennig, 1980). The number of mitoses is diminished and as a consequence, epithelial healing is impaired leading to recurrent erosions and ulcerations (Bonini et al., 2003). Denervation of the cornea limits the extent and increases the duration of wound closure (Wilson and Ambrosio, 2001). [In a model of NK created by surgical amputation of the trigeminal ganglion in albino rabbits, Akari et al demonstrated a delayed rate of healing, fewer desmosomes and excessive exfoliation of epithelial cells leading to persistent epithelial defects \(Araki et al., 1994\).](#)

365

Many theories have been proposed to explain the pathogenesis of NK, including, desiccation of the corneal surface due to diminished lacrimal secretions as tear secretion is nerve stimuli dependent (Belmonte and Gallar, 2011); impaired corneal sensitivity leading to diminished protective blink reflexes, abnormal epithelial cell metabolism with subsequent failure to resist the effects of trauma, drying, and infection; and the loss of trophic influences provided

371 by corneal nerve fibres (De Haas, 1962; Duke-Elder and Leigh, 1965; Heigle and Pflugfelder,
372 1996; Paton, 1926; Wilson and Ambrosio, 2001). In most cases it is probably a combination of
373 these factors, with a neurotrophic deficit playing a major role.

374 The reduced secretion of tear fluid and the loss of vitality of the epithelial cells can cause
375 a reduction in the presence of neurotrophins on the ocular surface, in particular NGF, which is a
376 neurotrophin essential to the development and survival of sympathetic and sensory neurons,
377 and for trophic support after neuronal injuries (Sacchetti and Lambiase, 2017). It is normally
378 present in the healthy cornea, where it regulates the proliferation and differentiation of
379 epithelial cells. NGF also appears to be involved in epithelial and stromal interactions that
380 induce stromal healing and remodelling. A reduced availability of NGF will result in
381 impaired nerve and cornea functions (Chen et al., 2014; Di et al., 2017; Park et al., 2016).
382 Reduced mitosis would lead to a slowing of or a dysfunction in the centripetal movement of
383 cells from the limbus, thus affecting the cells in the centre of the cornea. As the cells here
384 age, their ability to hold the tear film on the surface also reduces. This combined with the
385 effect of the altered quality and amount of tear fluid may reduce the ability of the tear film
386 to cushion the shearing stress of lid movements. The central cornea would then be most
387 vulnerable and this can explain the central location of epitheliopathy at onset of NK and the
388 subsequent ulcer. Reduced tear production is a major cause of decreased tear clearance with
389 consequent accumulation of toxic agents and pro-inflammatory cytokines on the ocular surface,
390 which may also be a contributing factor.

391 Excessive and rapid evaporation of tears from the ocular surface could be a source of
392 epithelial keratopathy in dry eyes. Rapid evaporation causes a drop in corneal temperature,

which in turn will trigger acute -and repeated stimulation of cold nerve sensors at the corneal surface. Over time, continuous stimuli will change the thermal sensor function into nociceptor (pain) sensor (Belmonte et al., 2009). Stimulation of peripheral nociceptors leads to the release of a variety of substances that can further stimulate the nociceptors and evoke release of pro-inflammatory mediators such as Substance P, CGRP, Neurokinin A (NKA), and Endothelin-3 (ET-3), and induce neurogenic inflammation.

Anatomical studies have shown a direct apposition of nerve terminals with dendritic cells, which are cells of the innate immune system. Neuropeptides released from nociceptors can induce degranulation or cytokine production in these cells. CGRP-containing nerve fibres are intimately associated with Langerhans cells (LC) in human epidermis and CGRP is found at the surface of some LC. In three functional assays CGRP inhibited LC antigen presentation. These findings indicate that CGRP may have immunomodulatory effects in vivo and suggest a locus of interaction between the nervous system and immunological function (Hosoi et al., 1993).

Infrequent blinking associated with NK can thus induce and sustain an inflammatory environment and perpetuate epithelial keratopathy. Furthermore, there is some evidence suggesting that healthy epithelial cells of the cornea may work as Schwann cells on the local denuded nerve fibres (Stepp et al., 2017). Loss of epithelial support will make nerves vulnerable to damage and improper function building a vicious cycle of evaporation - excessive stimulation - neurogenic inflammation – epithelial damage - nerve hyper/ improper activity – inflammation. Evaporation from the tear film is not balanced by corresponding increase in tear secretion thus leading to a hyperosmotic environment, which induces cell apoptosis and inflammation with an increased expression of matrix metalloproteinases (MMP) initiating a cascade of events which perpetuate and worsen the condition (Baudouin et al., 2013). These collagenolytic enzymes

(especially MMP-2 and -9) are produced by corneal epithelial and stromal cells themselves (Geerling et al., 1999). An imbalance between the activators and inhibitors of MMPs is the main driver for progression and chronicity of the stromal ulceration and collagen melting, which can eventually lead to corneal perforation and loss of vision (Fini et al., 1992). Corneal epithelial damage also impairs its ability to maintain a difference in electric potential between the outer and inner surfaces. Loss of the electro negative repulsive charge favours bacterial adherence. This combined with the loss of a whole host of antimicrobial peptides (Mohammed et al., 2017) that are normally present in the tear film and actively secreted by the epithelium, favours microbial invasion and infection. Infection in turn augments stromal melting.

The impact of preservatives on the ocular surface, especially benzalkonium chloride (BAK) used in topical eye medications, deserves special mention. BAK is a tensioactive and cytotoxic compound widely used as preservative in ophthalmic solutions. It is known to induce pro-inflammatory and pro-apoptotic effects proportional to its concentration and is responsible for multiple effects on the ocular surface, specifically the induction of dry eye and chronic inflammatory changes (Baudouin et al., 2010). BAK has also been shown to be neurotoxic (Sarkar et al., 2012), causing corneal hypoesthesia and nerve damage (Labbe et al., 2012; Martone et al., 2009). Moreover BAK may severely affect corneal wound healing, delaying corneal epithelial wound closure in animal models, even below the concentration (0.01%), found in most ophthalmic solutions (Kossendrup et al., 1985; Nagai et al., 2010; Sharma et al., 2011). *In vivo* and *in vitro* models showed the negative impact of BAK-containing solutions on damaged corneas (Liang et al., 2012). These models offer easy and reliable investigations of the effect of substances on the wound healing process. *In vitro* wound-healing assays using corneal cell monolayers involve the making of a standardized ‘scratch’ in the monolayer with a sterile

micropipette tip under an inverted microscope (Fig. 24). Cell proliferation as well as rate and extent of wound closure are easily followed and documented, allowing reliable investigations and comparisons on drug toxicity profiles. Although most active compounds used in glaucoma like beta-blockers or prostaglandin analogs are found to be almost neutral (Liang et al., 2012), BAK reliably shows concentration-dependent delay in wound healing, with concentrations as low as 0.001% being toxic and delaying wound closure. These models however do not take into account the additional effects of BAK on tear film, goblet cells, corneal nerves and inflammatory cells (Baudouin et al., 2010). Any non-healing corneal epithelial defect in an eye receiving potentially toxic compounds like preservatives, antibiotics, steroids or non-steroidal anti-inflammatory drugs should be considered as a possible iatrogenic consequence of therapy and cessation of medication should be considered as a first step before embarking on elaborate management regimes (Gomes et al., 2017).

The role of the conjunctiva in the pathogenesis of NK is not clear even though it undergoes significant changes during the disease process including a decrease of goblet cell density and loss of cell-surface microvilli. Gilbard and Rossi (Gilbard and Rossi, 1990) demonstrated that although the conjunctival changes in NK were consistent with increase in tear film osmolarity and surface changes as seen in dry eye disease, the corneal changes observed with denervation, including slit-lamp findings, morphologic changes and decreases in glycogen, were too severe and rapid in onset to be accounted for by osmolarity alone.

With greater degree of hypoaesthesia and anaesthesia, the patient has almost no symptoms. Medical attention is delayed until the disease progresses to a stage where vision is affected. However, the hypoaesthesia may affect only the denuded area (ulcer) with sensations persisting in the surrounding cornea. Paradoxically, NK can present with symptoms of

neuropathic corneal pain as seen after Herpes zoster ophthalmicus. There is likely to be a spectrum from increased sensitivity and decreased threshold (hyperaesthesia) to absence of corneal sensations, with the former leading to the latter as the disease progresses.

NK related to herpes related keratitis is an enigma. Recurrent HSK results in persistent epithelial defects in the cornea ipsilateral to the affected trigeminal pathway. This is associated with hyperosmolarity, reduced tear break up time, reduced tear secretion (Schirmer I test) and reduced sensations not only in the affected eye but also in the unaffected eye (Rousseau et al., 2015; M'Garrech et al., 2013; Jabbarvand et al., 2015). Unilateral herpes simplex and herpes zoster keratitis is associated with bilateral loss of corneal nerve receptors and dendritic cell infiltration (Hamrah et al., 2010; Hamrah et al., 2013; Cavalcanti et al., 2018). The findings are mirrored in studies on rabbits with unilateral trigeminal axotomy, wherein bilateral loss of corneal nerves and immune cell infiltration was demonstrated (Yamaguchi et al., 2016; Yamaguchi et al., 2013). This suggests that unilateral affection of the (central) trigeminal pathways could trigger bilateral responses probably via neurogenic inflammation. In humans, though clinical manifestations are predominantly unilateral it is possible that subclinical NK is present in the other eye as well, in some cases. Whether amelioration of signs and symptoms by treatment of the affected eye leads to resolution of changes in the other eye remains to be seen.

7.3 Natural History of NK

When cornea sensitivity is impaired or lost, a sequence of events is triggered at the ocular surface leading to NK and its consequences (Fig. 32).

- a. Tear secretion is reduced or abolished, the tear film is thinner and unstable. Mucin

distribution over the ocular surface is altered and irregular. The composition of tears changes with regard to growth factors, cytokines, antimicrobial peptides and ions adversely affecting epithelial homeostasis. Its physical ability to protect against lid shearing forces is diminished.

- b. Due to lack of trophic neuro-mediators, epithelial cells mitosis and maturation at the limbus and centripetal migration are slowed down. This results in the accumulation of older, less vital, pre-exfoliating cells in the centre of the cornea with poor ability to be wetted, which can be easily damaged by friction with the lids during blinks. Tear film changes and lack of trophic support may lead to epithelial irregularity and grayish appearance which may affect the quality of vision.
- c. Continuous epithelial damage results in chronic epithelial instability, with loss of effective tight junctions and zonulae occludens, and increased risk of bacterial adhesion and infection.
- d. With time, the tear film alteration, epithelial pathology and reduced ability to provide new cells, all combine to worsen the epithelial damage leading to an epithelial defect characterized by its central position and by the presence of rolled borders made of cells that are unable to adhere to the basement membrane possibly covered by denatured mucins or bacteria, which are no longer cleared by adequate tear production.
- e. Surface dryness, inflammatory cytokines and local epithelial damage leaves the underlying stroma open to the destructive activity of MMP resulting in stromal melts (Pflugfelder et al., 2005).
- f. The extent and progression of stromal damage is determined by the balance between activators and inhibitors of the proteases. Attempts at healing lead to unsuitable

collagen deposition, with irregular scar formation, loss of transparency and visual function.

g. Unchecked disease and ongoing metalloproteinase activity leads to perforation (Chotikavanich et al., 2009).

h. Eventually functional and anatomical loss of the eye occurs.

8. Clinical presentation and classification

Patients with NK will present in the early stage of the disease with symptoms of dryness, photophobia, and inability to read for a prolonged period of time due to epithelial changes and instability (see pathogenesis), impaired quality of vision and reduced blink. Symptoms are usually worse in the morning or in the presence of aggravating factors such as air conditioning, air travel, draught of hot air from car heating or prolonged use of some computers (draught of hot air from computer fans and reduced blinking associated with mental concentration) (Dua et al., 2014). Paradoxically, with worsening or severe disease, the symptoms of pain and discomfort may be less or absent due to sensory dullness related to hypoaesthesia or anaesthesia of the cornea. Symptoms of visual impairment appear when the central cornea is significantly involved. Clinical signs relate to those associated with the underlying condition and those due NK, usually a combination of the two.

8.1 Signs related to NK

Early signs are similar to those of dry eye with rapid tear-break up time, narrow tear meniscus and inferior one third conjunctival and corneal punctate staining with fluorescein (superficial punctate

keratitis SPK). The blink rate can be reduced and irregular (normal 17 blinks per minute) (Bentivoglio et al., 1997). The cornea reflex (lustre) becomes dull and the epithelium appears cloudy with epithelial irregularities. In NK related to laser refractive surgery (Ocular surface syndrome) (Alio et al., 2007; Ambrosio et al., 2008), SPK is centrally located and can wax and wane (Fig. 43 a-c). With increasing severity, the epithelial erosions coalesce and become larger (coarse erosions) and a frank epithelial defect, usually centrally located, appears (Fig. 43 d-f). Attempts at healing of the defect are slow and often incomplete. The area of the defect changes as the epithelium heals and breaks down repeatedly. Eventually the defect becomes permanent (persistent epithelial defect, PED) with smooth or rolled and opaque edges. The epithelium around the perimeter of the defect is loosely attached to the underlying Bowman's layer as evidenced by the sub-epithelial seepage of fluorescein dye, beyond the edge of the defect. The exposed stroma is vulnerable to the effect of proteases resulting in melting, that can lead to perforation (Fig. 43 g-i). The ulcer is usually sterile however secondary microbial infection can occur which can lead to rapid progression of melting and perforation. (Fig. 54). Stromal involvement can also manifest as edema, striae and Descemet's folds. Cells in the anterior chamber can be seen and frank hypopyon should be carefully evaluated and followed since it can be sterile or a sign of secondary infection. In vivo confocal microscopy examination, in the presence of frank corneal hypoaesthesia, can show an intact sub-basal plexus (pre-ganglionic affection of the Vth nerve) with a relatively better prognosis (Dhillon et al., 2016). In the majority of cases however, the sub-basal plexus is deficient.

Corneal vascularization is variable in its occurrence and severity. NK itself can cause stromal vascularization but wide variations related to the underlying cause, can be seen. Some infections like with acanthamoeba cause little vascularization whilst herpes virus infections cause the most (Faraj et al., 2016). Ocular surface inflammation may be obvious as conjunctival hyperemia or could be completely absent.

8.2 Signs related to underlying disease

555

556 Signs related to the underlying cause could manifest as lagophthalmos or reduced blink
 557 reflex, signs of previous herpetic keratitis with scarring and vascularization or patches of iris
 558 atrophy, lattice or granular dystrophy, enlarged beaded corneal nerves, scarring from previous
 559 corneal infections, limbal stem cell deficiency, advanced diabetic retinopathy or pan-retinal
 560 photocoagulation. Optic disc swelling or atrophy may suggest orbital or cranial lesions. Reduced
 561 or absent sensation in the dermatomes supplied by the trigeminal nerve which may be associated
 562 with other cranial nerve affection may give clues to the underlying cause. Seventh cranial nerve
 563 palsy may affect the prognosis of the disease from corneal exposure due to lagophthalmos and
 564 reduced blink reflex and can be modified by the presence or absence of a good Bell's
 565 phenomenon.

566

567 8.3 *Classification*

568 Traditionally NK has been classified into 3 stages as described by Mackie (Mackie,
 569 1995).

570 Stage 1 of neurotrophic keratopathy demonstrates the following:

- 571 • Rose Bengal staining of the inferior palpebral conjunctiva (lissamine green is now the
- 572 standard dye used instead of rose Bengal)
- 573 • Decreased tear breakup time
- 574 • Increased mucous viscosity
- 575 • Punctate corneal epithelial fluorescein staining

576 Stage 2 is characterised by:

- 577 • Epithelial defect - Usually oval and in the superior cornea
- 578 • Defect surrounded by a rim of loose epithelium
- 579 • Edges may become smooth and rolled
- 580 • Stromal swelling with folds in the Descemet's membrane
- 581 • Sometimes associated with anterior chamber inflammatory activity

582 Stage 3 is characterised by:

- 583 • Stromal lysis/melting
584 • May result in perforation

585 Dryness and visual aberrations are the main symptoms of NK and reduced or absent corneal
586 sensations, the main and arguably the pathognomonic clinical sign. However, with current
587 understanding of corneal nerve pathology using in vivo confocal microscopy and post-mortem
588 whole mount staining of corneal pathology it is evident that aberrant re-generation and hyper-
589 regeneration of nerves also occurs, which could by inference lead to corneal hyper-aesthesia and
590 account for the occurrence of symptoms that are out of proportion to the clinical signs (Al-Aqaba
591 et al., 2011b; Al-Aqaba et al., 2012; Wolter, 1964, 1966). This however is usually seen in some
592 cases in early disease and current available methods of evaluation do not allow the assessment of
593 increased sensitivity. Reduced sensitivity and the consequences thereof constitute the classical
594 manifestation of NK. Direct imaging of nerves has enabled a degree of quantification based on
595 nerve density, tortuosity, thickness, reflectivity and aberrations such as looping, coiling,
596 irregularity in diameter, presence of ‘growth cones’ and truncation (dead ends). It has also been
597 demonstrated that nerve anomalies can be localised to some parts of the cornea whilst others can
598 have normal physical appearance of nerves and their distribution. It is not clear whether altered
599 sensitivity is restricted to the areas of nerve anomalies or more generally reflected in the cornea.
600 Nevertheless, it is good practice to test sensations in the centre and in the peripheral four
601 quadrants. Patient symptoms appear to be more generalised, with no specific corneal/ocular
602 surface localisation, regardless of the location of nerve anomaly.

Although the Mackie classification has been in vogue for a number of years, we propose the following adaptation, which would be more clinically relevant and indicate severity and prognosis. Examples are given in figure ~~four~~three.

- Mild [Epithelial changes only without epithelial defect]: Epithelial irregularity without frank epithelial defect; tear film instability and symptoms (hyper-aesthesia) with reduced or absent sensations in one or more quadrants of the cornea.
- Moderate [Epithelial defect without stromal defect]: Frank persistent epithelial defect-and corneal hypo-aesthesia/anaesthesia.
- Severe [Stromal involvement]: Stromal involvement from corneal ulcer to lysis to perforation, with corneal hypo-aesthesia/anaesthesia.

Epithelial disturbance, frank non-healing epithelial defect and stromal lysis usually but not necessarily follow sequentially (Figs. ~~65-87~~) . All other clinical signs of NK are variable and do not appear or progress sequentially as is often determined by the underlying condition for example in a case of chemical burn the patient may present with severe NK without having progressed through NK of mild and moderate severity. It is important to understand the difference between an abrasion and an ulcer as both are technically ‘epithelial defects’. Abrasion implies the rubbing or scraping away of cells from the surface of an area of the cornea, skin or mucous membrane; whereas an ulcer is a breach of the continuity of the epithelium of any of the above mentioned tissues, due to sloughing related to inflammation and tissue necrosis. Abrasions generally heal rapidly while ulcers take longer to heal, festering as ‘non-healing epithelial defects’.

625 9. Diagnosis and Differential diagnosis

626

627 Diagnosis of NK is based on the clinical interpretation of the history, general examination of
628 the patient, slit lamp examination of the eye and findings of some diagnostic tests. Clinical
629 examination and tests are directed towards features of NK and of any possible underlying
630 condition.

631 9.1 Ocular symptoms

632 Symptoms of NK are elaborated in the section on clinical features and should be
633 specifically explored as the presenting symptoms of NK can vary according to the
634 severity of the disease. Other symptoms such as dryness, photophobia, lacrimation and
635 visual disturbance or impairment can be present and should be explored and documented.
636 There is lack of correlation between symptoms and signs. Neuropathic corneal pain can
637 be a presenting feature and severe corneal signs can be present with disproportionately
638 minimal pain.

639

640 9.2 Clinical History

641 Patients often have a history of features related to an underlying condition (table 2).
642 Previous hospital visits for ophthalmic and non-ophthalmic consultations, previous ocular or
643 brain surgery, ocular or head trauma, use of topical medication (specifically preserved eye drops)
644 and systemic medication (eg. neuroleptics and antipsychotic drugs). Systemic chronic conditions
645 such as diabetes and multiple sclerosis can be present. Topical anaesthetic misuse is often missed
646 unless suspected in individuals with specific professions (eg. welders, metal workers).

9.3 Examination

9.3.1 Neurological Examination

This includes assessing cranial nerve function, which may help to localize trigeminal damage. Concurrent abnormalities of the third cranial nerve with sixth cranial nerve may indicate damage in the cavernous sinus or localize an intracranial aneurysm. Pupillary abnormalities may indicate the status of third nerve, as well as defects, in the sympathetic innervation of the iris. The presence of an afferent papillary defect in association with corneal hypoesthesia would localize the lesion to the intra-conal orbit. Pupil reactions consistent with Adie's pupil have also been associated with alterations in corneal sensation.

Abnormalities of the 7th & 8th cranial nerve may indicate damage from acoustic neuroma or neuro-surgery. Damage to 7th nerve may can lead to exposure of the ocular surface due to lagophthalmos, which will worsen prognosis of patients with NK especially in the absence of Bell's phenomena.

9.3.2 Ophthalmic Examination

9.3.2.1 External exam (eyelids and conjunctiva) ~~Eyelids~~

Eyelid function is critical to the prognosis of neurotrophic keratitis and progression of advanced disease. Lid features to note are ectropion, entropion, misdirected lashes or ptosis (oculomotor nerve damage or mild ptosis in the presence of corneal infection). Lid scarring may be present secondary to removal of periocular infiltrative tumors or chemical or thermal burns. The conjunctivae in NK patients generally show a lack of conjunctival injection i.e. 'white' eye. The presence of 'red eye', however, would indicate the presence of co-existing inflammation

Formatted: Font: (Default) Times New Roman, 12 pt

usually related to secondary infection. Subconjunctival fibrosis may be present, which could be associated with chronic autoimmune disease and/or severe dry eye.

9.3.2.2 *Slit lamp examination*

Examination of the cornea in NK with the slit lamp may reveal a spectrum of changes, as described in the section on ‘Clinical features’. Other corneal changes which may indicate previous infections or recurrent corneal ulceration should be noted, such as the presence of vascularization and/or scarring. Keratitis related Herpes virus infection is the commonest cause of corneal vascularization (Faraj et al., 2016). Anterior chamber examination may reveal flare, keratic precipitates, cells or frank hypopyon from active anterior uveitis, which may result from non-viral corneal infection or inflammatory reaction from herpetic kerato-uveitis. Iris examination may show sectoral transillumination indicating iris atrophy secondary to herpes kerato-uveitis/iris pigment epithelialitis.

9.4 *Vital Staining*

Fluorescein and lissamine green dyes are useful in assessing subtle changes in the epithelium (mild NK) and frank epithelial defects (moderate and severe NK). As tear film anomalies are integral to the pathophysiology of NK, tear assessment is important. Besides other tests such Schirmer’s test, both these vital dyes are useful in assessing ‘dry eye’ signs such as tear meniscus height, tear breakup time and punctate corneal and conjunctival erosions. Assessment of tear film osmolarity is considered to be important in dry eye disease but its role in NK is not clear (Belmonte et al., 2017). Ocular fundus examination may reveal diabetic retinopathy, optic nerve pallor (multiple sclerosis) or swelling from an intracranial neoplasm.

689 The above account illustrates that, as with any ocular assessment, with NK too, it has to be
 690 thorough and complete and not restricted to the cornea or ocular surface.

691 9.5 *Diagnostic tests*

692 9.5.1 *Corneal Sensation*

693 Assessment of corneal sensation is fundamental to the diagnosis of NK. The algorithm
 694 for diagnosis is given in the diagram (Fig. [98](#)). Clinically, corneal sensation is assessed by using
 695 a 'wisp' of cotton applied to both corneas (Fig. [109a](#)). Patient's reaction is noted and compared
 696 between the eyes. NK patients typically show reduced blinking/sensation to the stimulus.
 697 Corneal sensation is reduced or normal, if it is normal then NK unlikely. Some authors have
 698 stated that an absence of the nasal-lacrimal tearing reflex along with ipsilateral loss of sensation
 699 in the nasal mucosa presents a high risk for subsequent neurotrophic corneal ulceration, so there
 700 may be a basis for testing this.

701 Corneal sensation can be (semi)quantitatively measured by the Cochet-Bonnet
 702 aesthesiometer or the Belmonte non-contact gas aesthesiometer (BNGA) (Fig. [109b](#) and [109c](#)).
 703 The former is a contact instrument and the latter is not. With the Cochet-Bonnet aesthesiometer,
 704 corneal sensitivity is assessed observing the patient's subjective reaction to different lengths of a
 705 protruding nylon filament applied to the cornea which is extended from 60mm to 5mm with a
 706 corresponding change in force from 11 to 200 grams/mm. After touching the cornea in the
 707 quadrant to be tested, pressure is applied on the filament to induce a gentle bend. At this point
 708 the patient should appreciate the touch of the filament tip. The length is reduced in 5mm steps
 709 until the patient appreciates the touch. The longer the length at which the patient feels the touch

710 of the filament, the higher the corneal sensitivity. Measurements are performed in each quadrant
 711 of the cornea and data recorded accordingly (Golebiowski et al., 2011).

712 The BNGA works by stimulating the cornea with a calibrated gas emission from an
 713 injector kept close to the cornea and subsequent blink response. The BNGA is mounted on a slit-
 714 lamp (similar to an applanation tonometer) with the gas injection tip kept perpendicular to the
 715 cornea, the subject is instructed to look at a fixation target at 3 m, and the injection tip is kept
 716 5mm away from the surface, (the distance is measured with a transparent ruler). Subjects are
 717 instructed to close and open their eyes just before triggering the stimulus. By varying the flow,
 718 temperature and composition of gas (CO₂ concentration) this device can assess different
 719 components of corneal sensation i.e. mechanical, chemical and thermal sensitivity. The
 720 technique has been found to be safe and reproducible and its 'non-contact' nature makes it safer
 721 than contact methods (Belmonte et al., 1999; Teson et al., 2012).

722 9.5.2 *Imaging Corneal Nerves*

723 In vivo confocal microscopy (IVCM) (Fig. 110) allows qualitative and quantitative
 724 assessment of corneal nerves in health and disease. Nerve density, tortuosity, angulation,
 725 thickness and reflectivity are assessed using image analysis programmes. IVCM has been used to
 726 detect corneal nerves changes in a variety of conditions such as keratconus, bullous keratopathy,
 727 diabetic neuropathy and herpes simplex keratitis (Al-Aqaba et al., 2011a; Al-Aqaba et al., 2011b;
 728 Cottrell et al., 2014; Messmer et al., 2010). In diabetic neuropathy, analysis of corneal nerve
 729 density and morphology has demonstrated a correlation between reduction in fibre
 730 density/branching and severity of somatic neuropathy. The method is sensitive enough to detect
 731 significant structural abnormality in the corneal nerves of patients deemed to have mild diabetic
 732 neuropathy by conventional tests and can help detect onset of diabetic peripheral neuropathy

prior to clinical manifestation. In pre-ganglionic (trigeminal ganglion) lesions and partial ganglion lesions, corneal sensitivity can be absent or diminished but IVCN demonstrates a normal sub-basal plexus with mild NK. In post-ganglionic or complete ganglionic lesions the sub-basal plexus is attenuated or lost, corneal sensations are reduced and the risk of developing moderate to severe NK is high (Dhillon et al., 2016). Accurate imaging and quantitative analysis of images of sub-basal and stromal nerves can be affected in corneas presenting with severe NK due to the possible influence of concurrent stromal oedema, infiltration, melting or scarring.

9.5.3 Anterior Segment Optical Coherence Tomography (ASOCT)

Fourier domain ASOCT can demonstrate corneal nerve abnormalities (radial keratoneuritis) such as during active acanthamoeba keratitis (Yamazaki et al., 2014) and can be used to assess treatment response. However, current instrumentation has insufficient resolution to resolve corneal nerve architecture changes where the sole abnormality is loss of corneal sensation. ASOCT comes in handy to assess corneal thickness changes as may occur during moderate to severe NK; providing both morphometric and qualitative data. ASOCT can be used for measuring the depth of stromal ulcerations and stromal thickness changes occurring over time in NK (Fig. 124), facilitating the diagnosis of cases at risk of perforation and improving the follow-up analysis after surgical tectonic grafts of amnion or corneal transplantation (Nubile et al., 2011).

9.6 Differential diagnosis

Several chronic diseases can lead to NK and others can mimic NK, the key distinction being the alteration/absence of corneal sensation. The terms primary and secondary NK have been used as descriptors but there ~~is~~are no differences clinically in the corneal manifestations

once the process is driven by loss of trophic and sensory function. Systemic causes such as trigeminal nerve damage from tumour, trauma or surgery, or neuropathy associated with diabetes and multiple sclerosis can be considered as examples of primary NK whereas damage to the corneal innervation from direct insult to the cornea such as following viral infections, corneal transplantation or refractive surgery, can be considered as examples of secondary NK. Central and peripheral NK are term that also reflect the site of lesions that can cause NK, analogous to primary and seconday NK. In central NK corneal and conjunctival sensations are likely to be affected compared to peripheral NK where only corneal sensations are likely to be predominantly affected. In the majority of cases NK is a unilateral disease. Where the cause is diabetic neuropathy or multiple sclerosis it can be bilateral.

Dry eye disease, contact lens related disorders, blepharo-keratoconjunctivitis, limbal stem cell deficiency, exposure keratopathy, radiation keratopathy, topical drug and preservative toxicity and chronic eye rubbing are important conditions that can have overlapping features with NK and may remain as independent entities until corneal sensitivity is affected.

10. Management

Left untreated, NK can evolve into a devastating condition culminating in anatomical loss of the eye. Short of this, loss of vision is common even with treatment. Management of NK can be divided into medical management, non-surgical intervention and surgical management. These can be considered in a step-ladder approach according to NK stage/severity but are not exclusive as often a combination of options may need to be considered. The objective of treatment is to arrest progression and reverse NK changes that have occurred at the time of presentation. In mild

NK (stage 1), the objective is to prevent epithelial breakdown and encourage healing of epithelial erosions. In moderate NK (stage 2), the objective is to encourage re-epithelialisation of the denuded stroma and prevent progression to stromal melting. In severe NK (stage 3), the objective is to prevent perforation and promote healing. Throughout the course of NK maintenance of comfort and optimizing vision are also therapeutic considerations.

10.1 Medical Management of NK

Considerations for the medical management depend upon the severity / stage of NK and pathology of the underlying disease process. Therapeutic approaches are broadly divided into strategic areas that encompass categories of treating the underlying disease process, treating any concurrent infections, preventing disease progression, promoting epithelialisation, providing tear replacement, reducing inflammation, preventing stromal tissue loss or perforation and avoiding complications. The current step-ladder of interventions for NK according to severity is summarised in table 3.

10.1.1 Treatment of concurrent inflammation

10.1.1.1 Infection

Culture or PCR of forniceal swabs to identify common and unusual pathogens that may be present in abundance on a compromised ocular surface driving inflammation through activation of innate immune responses, is essential (Kugadas and Gadjeva, 2016). Identified organisms (bacteria, fungi, and viruses) should be treated. However, when infection is suspected but cultures are negative, empirical treatment with Azithromycin 1g orally for 3 days is advised. ~~Due to false negatives, empirical treatment with Azithromycin 1g orally for 3 days is~~

~~advised.~~ For persistent epithelial defects, secondary infection delaying healing should be excluded and the eye treated with broad spectrum topical antibiotics. Wherever possible, toxic aminoglycosides such as gentamicin should be avoided unless sensitivities dictate otherwise. Topically administered quinolones can also be toxic to the ocular surface (Ayaki et al., 2012; Mencucci et al., 2011; Walter and Tyler, 2001). Drug toxicity should be suspected when initial clinical improvement changes to clinical worsening and increased inflammation. The ‘up-down’ test, where in the upper bulbar conjunctiva appear white compared to the lower injected bulbar and fornicial conjunctiva, is a useful early indicator of drug toxicity. (Dua et al., 2012).

10.1.1.2 *Minimise ocular irritants and conservative treatment*

Awareness of iatrogenic causes of ocular toxicity is critical (Dart, 2003). All preserved therapy should, wherever possible, be discontinued. Detection of corneal deposits such as fluoroquinolone crystals (ciprofloxacin, ofloxacin) (Claerhout et al., 2003; Mitra et al., 2007), or hydroxyapatite formation due to a combined effect of hyaluronates and phosphates (Bernauer et al., 2006a), or calcific deposits after the use of steroid-phosphate (Schlotzer-Schrehardt et al., 1999), retinoic acid (Avisar et al., 1988), or lubricant phosphates (Bernauer et al., 2006b) should lead to clinical approaches that minimise potentially damaging drug/chemical precipitation reactions on the ocular surface.

Patients should also be advised to refrain from using irritating peri-ocular cosmetics, increase humidity by wearing protective moisture chamber wrap-around glasses or goggles, and consider increasing dietary omega-3 fatty acids (Eicosapentaenoic acid (EPA)) or linoleic acid and gamma-linolenic acid (Flaxseed oil). Fish oils have been shown to provide modest benefit to

the ocular surface by inhibiting pro-inflammatory mediators (Prostaglandin E2, Leukotriene B4, IL-1 and TNF α) (Kangari et al., 2013).

10.1.1.3 *Reduce Inflammation*

The use of non-preserved topical medications is essential to minimise ocular surface inflammation. Meibomian gland dysfunction should be treated with warm compresses possibly with the aid of proprietary eye-lid warming devices, lid massage and hygiene with diluted sodium bicarbonate or commercially available lid hygiene wipes. The use of matrix metalloproteinases inhibitors in the form of low dose tetracyclines or macrolides is advised. The mainstay is with the use of topical non-preserved glucocorticoids such as prednisolone or dexamethasone (Geerling et al., 2011). Delayed wound healing related to steroid medication, pharmacokinetically only occurs at higher doses or with longer duration of treatment. Nevertheless, inhibition of stromal healing, may increase the risk of corneal stromal melting and perforation, thus their use should be considered with caution. Vigilant screening for steroid-related raised intraocular pressure and optic neuropathy is required. Soft steroids such as medroxyprogesterone 1%-2% and androgens (if available) may ameliorate this risk. Topical non-steroid anti-inflammatory drugs (NSAID) treatment does not improve the healing process.

NSAIDs are generally avoided due to their epithelial toxicity and the risk of corneal ulceration (Guidera et al., 2001; Gaynes and Fiscella, 2002; Lee and Himmel, 2006; Feiz et al., 2009):-

Topical ciclosporin is only licensed for use in primary or secondary dry eye disease. Ciclosporin 0.1% (Ikervis® SDU) is licensed for severe keratitis of dry eye disease not responding to ocular lubricants. In the US and Far East, Ciclosporin 0.05% (Restasis®) may be a useful alternative. PADciclo 0.06% is currently undergoing clinical trials. The veterinary preparation, Ciclosporin 0.2%, (unlicensed, Optimune®) may also be considered if an ointment

with lubricating properties is required. Although tacrolimus 0.03% to 0.1% has been shown to be effective in combating ocular surface inflammation, its use in the context of NK has not been studied (Fukushima et al., 2014; Kiiski et al., 2014).

10.1.2 Tear substitution

Ocular lubricants reduce biomechanical shear forces and dilute pro-inflammatory mediators in the tear film thereby promoting epithelialisation. They are generally classified according to viscosity ranging from low to high and are summarised in table 4. Due to the toxicity associated with preservatives (Baudouin et al., 2010; Geerling et al., 2001; Gomes et al., 2017), unpreserved lubricants are prescribed, many of which can be bought over the counter by the patient. Carmellose agents are cytoprotective (Garrett et al., 2007), and hyaluronate ligation to CD44 expressed on injured ocular surface epithelial cells, deliver anti-inflammatory properties in addition to facilitating epithelial wound healing (Gomes et al., 2004). Other compounds such as guar gums, liposomes and soybean/mineral oil combinations, help stabilise the phospholipid layer whilst other agents confer osmoprotection (glycerine, L-Carnitine, erythritol, threalose). In patients with filamentary keratitis, mucolytics (acetylcysteine 5-10%) may be beneficial. Recent clinical trials indicate promising results for the use of diquafosol 3% (a P2Y2 receptor activator that improves mucociliary clearance and mucin production) and rebamipide 2% (that stimulates transmembrane mucin MUC16 biosynthesis) in multifactorial dry eye disease, although the exact benefit for NK is yet to be determined. Alternative non-preserved lubricants such as saline 0.9% (that has no excipients) or balance salt solution should be considered in resistant cases.

Nutritional tear substitutes (serum eye drops) are considered when all treatment options have been exhausted. Unlike other pharmaceutical tear supplements, nutritional substitutes contain

864 substances that are also present in natural lacrimal tears and support ocular surface epithelial
 865 growth and regeneration. These include growth factors (epidermal growth factor and
 866 transforming growth factor beta), Vitamins (A, C), glucose, natural antimicrobials (surface IgA,
 867 defensins, lysozyme), and proteins involved in wound healing (fibronectin) (Rauz and Saw,
 868 2010). Most commonly used are autologous serum eye drops (Azari and Rapuano, 2015;
 869 Semeraro et al., 2014; Turkoglu et al., 2014), but there is a risk of instilling circulating antibodies
 870 or pro-inflammatory mediators in patients with systemic diseases e.g. Multiple sclerosis, mucous
 871 membrane pemphigoid that have the potential to exacerbate disease processes in the eye.
 872 Allogeneic serum eye drops (available in the UK, Germany, New Zealand) are obtained from
 873 young healthy male donors and avoid cyclical oestrogen hormone variances that may have pro-
 874 inflammatory effects on the surface of the eye. Human umbilical cord serum has been shown to
 875 contain higher levels of growth factors, including nerve growth factor, and other constituents
 876 similar to those in tears, and has been used to treat a variety of ocular surface conditions
 877 including NK (Yoon et al., 2005; Yoon et al., 2007). The response to cord blood serum appears
 878 to be related to the severity of NK with mild to moderate (stages 1 and 2) lesions responding
 879 quicker than severe (stage 3) defects. (Erdem et al., 2014). ~~Human cord blood serum eye drops~~
 880 ~~has greater concentrations of nerve growth factor and other mediators but s~~However, small
 881 volumes obtained from the placenta, limits general use. Platelet-rich plasma (PRP) is abundant in
 882 growth factors that promotes ocular surface regeneration (Hartwig et al., 2004; Hartwig et al.,
 883 2005). Despite the differences in methods used to prepare this product for clinical use, studies
 884 indicate that PRP gives better results than autologous serum and can lead to healing of persistent
 885 epithelial defects where autologous serum drops have failed. They also have a good safety
 886 profile (Kim et al., 2012; López-Plandolit et al., 2010; Soni and Jeng, 2016). Its content of

biologically active proteins, growth factors, and biomaterial scaffolds make PRP a therapeutic agent promoting ocular surface wound healing and regeneration (Anitua et al., 2016). PRP has also demonstrated efficacy, as a monotherapy, in the management of post laser refractive surgery 'ocular surface syndrome' (Alio et al., 2017).

10.1.3 Prevent stromal tissue loss

Stromal degradation occurs after the release of proteolytic enzymes from recruited inflammatory cells, activation of clotting and kinin cascades that induce further inflammation and stromal loss. Matrix metalloproteinases inhibitors (oral tetracyclines and topical acetylcysteine) restrict neutrophil collagenase and epithelial gelatinase gene expression, suppress alpha-1 antitrypsin degradation and scavenge reactive oxygen species (Ogut et al., 2016; Hahn et al., 2016; Abdul-Hussien et al., 2009; Sekundo et al., 2002). Ascorbate applied topically or given systemically, provides cofactors for collagen synthesis as well as scavenging for oxygen free radicals. Topical citrate, if available, is a calcium chelator inhibiting neutrophil degranulation and release of proteolytic enzymes as well as inhibiting collagenases (Parker et al., 1985).

906 10.1.4. Biological medical products

907 Drugs given systemically targeting mediators that fuel inflammation or delay wound
 908 healing have gathered momentum over the past two decades, although very few biologics have
 909 been licensed for ocular use. Topically administered biologics or biosimilars provide an
 910 attractive area for drug development. Murine NGF (Bonini et al., 2000; Lambiase et al., 1998),
 911 Substance P and Insulin-like growth factor (Yamada et al., 2008) were the first mediators to
 912 show encouraging results (Fig. 132). A number of novel treatment modalities have emerged
 913 through clinical trials and are available for clinical use. These include recombinant human NGF
 914 (rhNGF, cenegermin (betaNGF) (European Medicines Agency, 2017), lifitegrast 5%
 915 (lymphocyte function-associated antigen-1 (LFA-1) antagonist) (Perez et al., 2016),
 916 ReGeneraTing Agent [RGTA] – matrix therapy agent, Cacicol20, Thymosin beta 4, Conenzyme
 917 Q10, Substance P, Netrin-1 (class of proteins involved in axon guidance and cell migration) and
 918 Nexagon® (an antisense oligonucleotide that downregulates expression of the gap junction
 919 protein Cx43, which is increased in pathological conditions with persistent epithelial defects)
 920 (Guerra et al., 2017). Many of these agents promote healing in a generic way by combating
 921 inflammation (lifitegrast) or rejuvenating the stroma by providing binding sites for growth
 922 factors to promote healing (RGTA). NGF specifically targets the deficit in NK by replacing the
 923 nerve growth factor and promoting epithelial healing and nerve health.

924 Cenegermin is a recombinant form of human nerve growth factor (rhNGF) produced in
 925 *Escherichia coli* as a pro-peptide, which is later cleaved to mature NGF. The molecule is
 926 identical to human NGF (European Medicines Agency, 2017). The European Medicines Agency
 927 recently (July 2017) granted Cenegermin 20 µg/ml (Oxervate®) full marketing authorization for
 928 the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) NK in adult

929 patients by, making it the first approved medical treatment for this specific indication. The
 930 efficacy and safety of cenegermin were evaluated in two independent, multicentre, randomised,
 931 double-masked, vehicle-controlled clinical studies (NGF0212 and NGF0214) in patients with
 932 moderate or severe NK refractory to non-surgical treatments. In both studies patients received
 933 cenegermin or vehicle 6 times daily in the affected eye(s) for 8 weeks, and were followed-up.
 934 Study NGF0212 (NCT01756456) conducted in Europe, enrolled a total of 174 patients (mean
 935 age 61 ± 16 years); 156 patients were assessed independently for efficacy, comparing two
 936 different dosages of the medicinal product with 20 and 10 µg/ml cenegermin to vehicle (52
 937 patients per arm) (Mantelli et al., 2017; Sinigaglia and NGF Study Group, 2014). Study
 938 NGF0214 (NCT02227147), run in US, enrolled 48 patients (mean age 65 ± 14 years) treated with
 939 cenegermin 20 µg/ml or vehicle (24 patients per arm) (Chao et al., 2017). ~~A summary of the~~
 940 ~~results of the two studies in relation to e~~Complete corneal healing of the persistent epithelial
 941 defect or corneal ulcer (the ~~key efficacy primary~~ endpoint, defined as the greatest diameter of
 942 corneal fluorescein staining <0.5 mm) after 4 and 8 weeks of treatment for patients who received
 943 cenegermin 20 µg/ml or vehicle ~~was compared. is given in table 5. There was a statistically~~
 944 ~~significant improvement to complete healing of the cornea at 4 and 8 weeks of treatment (58.0%~~
 945 ~~and 74.0% respectively) compared to vehicle (19.6% and 43.1% respectively) (p <0.001 and~~
 946 ~~<0.002) in study NGF 0212. In study NGF 0214 the difference was statistically significant at 8~~
 947 ~~weeks of treatment (69.6% with cenegermin and 29.2% with vehicle, p<0.006).~~

Formatted: Indent: First line: 0 cm

Formatted: Font: Font color: Auto, English (U.S.)

948

949 10.2 Non-surgical interventions

950 10.2.1 Eyelid closure

951 Tarsorrhaphy, the suturing of the eyelids to narrow the interpalpebral fissure is a
 952 cornerstone of NK management. Non-surgical techniques that can be used as an alternative to
 953 tarsorrhaphy include eyelid closure with tape, pressure patching, pad and bandage and botulinum
 954 toxin injection induced ptosis. In principle these have the same objective of covering the cornea,
 955 protection against the environment and effects of lid blinks. Contact lenses may also serve a
 956 similar purpose.

957 Placing an adhesive tape (transpore) across the closed eyelids is a simple intervention to
 958 keep the lids closed. ~~This is routinely employed by anesthetists to prevent exposure of the cornea~~
 959 ~~during surgery under general anesthesia. When used in the context of non-healing epithelial~~
 960 ~~defects of the cornea.~~ The limitation of taping is that if repeated removal and (re) application is
 961 required to instill eye drops or examine the eye, the delicate skin of the lids can excoriate and be
 962 bruised. The 'Apache patch' and invention of Mr B Donaldson of Aberdeen, Scotland, is a clever
 963 eye patch device which has two components, a 'T' shaped part for the upper lid with adhesive
 964 backing to the horizontal limb and a small rectangular part, with adhesive backing, for the lower
 965 lid. The ~~lower end of the vertical limb can be affixed to the part on the lower lid with Velcro.~~
 966 ~~This allows the~~ Velcro components canto be separated and reattached without removing the
 967 device from the lids. The Frost suture (can be considered a surgical intervention), which
 968 involves the placement of suture (4 '0 silk) horizontally through the skin of the upper (or lower)
 969 lid close to the lash line, serves a similar purpose. ~~The suture is cut to desired length and the two~~
 970 ~~ends tied. The suture can then be used as a 'handle' to pull the upper lid down (or the lower lid~~
 971 ~~up) and close the eye and keep it closed by fixing the suture to the cheek (or forehead) with~~
 972 ~~adhesive plaster.~~ Use of an eye pad with tape or bandage provides complete closure with some
 973 pressure. Usually two pads are used, one folded in half and applied on the closed lids to fill the

space of the anterior orbit, and the other placed on this and attached with a couple of strips of tape running from the forehead to cheek or held in place with an eye bandage. These are useful when closure for the whole day is required and not when the eye has to be opened frequently during the day. The drawback of needing to undo the patch or eyelid tape every time an eye drop is due has to be administered, makes them impractical. Importantly, care has to be taken to ensure that the lids do not open under the patch as this would allow the patch to rub against the cornea and aggravate the condition.

Botulinum toxin induced ptosis is an exception to the above. It provides a safe, rapid and effective means of closing the eye whilst still allowing for easy access to examine or instill eyedrops (Fig. 143). An injection of botulinum toxin is administered at the upper border of the superior tarsal plate or over the belly of the levator palperae superioris muscle and induces paralysis thereof causing the upper lid to droop and completely cover the cornea. The effect typically lasts 6 to 12 weeks. The number of units, dilution and volume to be injected varies according to form of botulinum toxin used. Another consideration is that the effect of the toxin is not immediate and can take several hours or a couple of days. Hence repeat injections should be avoided in the same week. In cases where only partial closure occurs, lagophthalmos may result in exposure and compound the problem and a further injection of botulinum toxin may be required (Kirkness et al., 1988; Schilimow and Wiechens, 2016).

10.2.2 Therapeutic Contact Lenses

Therapeutic contact lenses are fitted to maintain the integrity of the ocular surface tissues where improvement of vision is secondary benefit. Commonly used biomaterials are silicone hydrogels and rigid gas permeable, that are fitted as corneal, limbal, semi-scleral or scleral

lenses. Rigid gas permeable scleral contact lenses are vaulted away from the cornea and supported by the anterior sclera. The design creates a reservoir between the lens and cornea that captures therapeutic substances and increases retention time of therapeutic agents and lubricants on the ocular surface. One such device is the prosthetic replacement of the ocular surface ecosystem (PROSE) device. The use of contact lenses in the context of NK must be accompanied by extreme vigilance. The reduction of sensation reduces 'alarm' signals for infection. If used, prophylactic use of topical non-preserved antibiotics is advised (Baenninger et al., 2014).

Innovative devices using a combination of amniotic membrane and a contact lens are in vogue. The OmniLenz® and Prokera™ (see later) are examples. OmniLenz® consists of a soft contact lens lined with a circular disc of vacuum dried amniotic membrane and is applied directly on the corneal surface. The amniotic membrane rapidly hydrates and provides a soft biological cover to the defect. It is suggested that the release of molecules from the amniotic membrane favour healing. Evidence from clinical trials is lacking though anecdotal experience with single cases has shown a beneficial effect.

10.2.3 Punctal Occlusion

~~The tear film contains many factors that aid in corneal epithelial and stromal healing. These include growth factors, such as EGF, TGF, TGF- β , bFGF, HGF, and vitamins A and C, and fibronectin. Increasing the amount of tears in the eye can aid in the healing of epithelial defects and nonhealing ulcers. In addition, tears lubricate the surface of the eye, remove disease-causing pathogens, and protect healing epithelium. Low volume of tears can be compensated for either by adding artificial tears or decreasing tear egress from the palpebral fissure. Tear substitutes do not contain the growth factors and vitamins present in natural tears. Punctal~~

occlusion increases the retention of natural tears enhancing the healing process (Cohen, 1999; Guzey et al., 2001). Punctal occlusion can be performed by various methods (Baxter and Laibson, 2004). Punctal plugs – these can be temporary or short acting collagen plugs, or permanent punctal or canalicular plugs. The punctae can be also be permanently occluded with thermal cautery. Other methods of occluding the puncta, include argon laser, suturing of the punctum, or canalicular ligation (DeMartelaere et al., 2006; Hutnik and Probst, 1998; Liu and Sadhan, 2002).

Punctal plugs can be associated with complications, such as pyogenic granulomas, bacterial colonization, extrusion, and local irritation (Kim et al., 2005; Sugita et al., 2001; Tai et al., 2002). Timing is critical as early insertion during active inflammation may lead to the accumulation and stagnation of tears loaded with pro-inflammatory cytokines and pro-inflammatory mediators gene expression on the ocular surface (Tong et al., 2016).

10.3 *Surgical intervention*

Surgery is often required in advanced disease refractory to medical management, mainly in moderate and severe NK (stages 2 and 3). Medical and surgical options are not mutually exclusive and are often combined.

10.3.1 *Permanent punctual occlusion*

Where temporary punctual occlusion has been successful in improving the tear reservoir, epiphora has not occurred and there is no prospect of a return of normal lacrimation then permanent punctual occlusion may be considered. This is particularly beneficial in patient likely to require lifelong punctual occlusion in whom punctal plugs can give rise complications stated

above. Cauterisation of the vertical part of the canaliculus and punctum with heat is the standard method to achieve this.

10.3.2 Tarsorrhaphy

Tarsorrhaphy provides a more definitive closure of the eyelids by approximating the upper and lower lids. This is considered as the gold standard in NK treatment in several centres (Fig. 154). Closure of the lids protects the cornea from the environment, prevents epithelial damage by the friction caused by eyelid movement especially when the lid margins are irregular and keratinized (Cosar et al., 2001), conserves tear fluid and provides a reservoir of tears to keep the eye constantly moist and theoretically, the approximation of the vascular palpebral conjunctiva to the corneal surface affords additional unknown benefit. Tarsorrhaphy can be temporary or permanent, depending largely on the natural history of the underlying etiological condition (Allen and Malinovsky, 2003), partial (lateral, medial, central) or complete, depending on the severity of NK.

Of the various techniques of performing a tarsorrhaphy, the most common is suturing the lids to each other over bolsters. This tarsorrhaphy reverses when the suture is removed and often the suture loosens after a few days or weeks. If the lid margins are denuded prior to suturing, the tarsorrhaphy is permanent, and if they are not, it is temporary. The advantage of (lateral) tarsorrhaphy over corneal patching is that the eye can be examined, the patient has vision, and the risk of infectious keratitis is reduced (Ali and Insler, 1986; Cosar et al., 2001; Panda et al., 1999). Tarsorrhaphy should be considered in all cases of persistent epithelial defects that fail to respond to medical treatment and/or non-surgical interventions (Tuli et al., 2007). If healing occurs, the tarsorrhaphy opening may be enlarged after a few weeks, but opening the tarsorrhaphy prematurely may result in a recurrence of corneal epithelial breakdown, especially

1062 if total corneal anaesthesia persists.

1063 10.3.3 Debridement

1064 At times, the leading edges of the healing epithelium may thicken and become rolled or
 1065 heaped, impeding migration across the defect. In such cases, the epithelium at the edges of the
 1066 defect may be removed, effectively enlarging the defect. This triggers the healing response in the
 1067 surrounding epithelium promoting migration to close the defect (Katzman and Jeng, 2014).

1068 10.3.4 Amniotic Membrane Transplantation (AMT)

1069 The amniotic membrane (AM) is a versatile tissue that has caught the imagination of
 1070 ophthalmologists and has been used for a wide variety of indications across several ophthalmic
 1071 subspecialties. Its efficacy has been adequately demonstrated (Azura-Blanco et al., 1999; Dua
 1072 et al., 2004; Gomes et al., 2005), but equally it is at times used “as something to do rather than
 1073 something that does” (*hsd*) (Clare et al., 2012; Joseph et al., 2001; Rahman et al., 2009). AM can
 1074 be used as a graft (inlay) or a patch (onlay) (Bonini et al., 2003). When the AM is applied such
 1075 that epithelium migrates on the membrane and the amnion becomes incorporated in the cornea, it
 1076 is termed a ‘graft’ (Fig. 165). Conversely if the healing epithelium migrates under the AM and
 1077 the amnion later falls off or is removed, it is termed a ‘patch’. At times two membranes can be
 1078 used one as a graft and the other as a patch over the graft. AMT can be combined with
 1079 tarsorrhaphy but individually they have shown efficacy in the treatment of refractory
 1080 neurotrophic corneal ulcers (Khokhar et al., 2005). Multiple pieces of AM cut to fit the shape of
 1081 the defect can be stacked and finally covered by a graft or patch (Prabhasawat et al., 2001). The
 1082 amnion allows keratocytes to migrate in the AM stroma and lay down collagen/scar tissue, which
 1083 helps build the tissue at the site of melt. Multiple layers of amniotic membrane can integrate into

1084 the corneal stroma with resulting increase in corneal thickness; however keratocyte-mediated
 1085 wound healing and remodeling of the incorporated amniotic tissue induces progressive
 1086 contraction and changes in tissue transparency (Nubile et al., 2011). In the context of NK it has
 1087 proven efficacy and is usually used in severe NK (stage 3) but has been used in mild and
 1088 moderate NK (stages 1 and 2). (Gris et al., 1999).

1089 Fresh, cryopreserved (Amniograft), freeze dried (Ambio dry) and vacuum dried
 1090 (Omnigen) amnion are available and all have demonstrated efficacy to a lesser or greater extent,
 1091 with the latter two offering advantages of ease of storage and transportation at room temperature.
 1092 All human derived tissue carries a serious risk of transmission of infectious disease. Though
 1093 'fresh' amnion is still used in some parts of the world, the practice does not allow sufficient time
 1094 for a thorough testing for microbial contamination. Where serological testing is performed, the
 1095 donor is tested at the time of donation and the tissue quarantined for 6 months, when a repeat test
 1096 is performed. The material is released for clinical use only when both tests are negative. With
 1097 PCR testing on tissue samples, it is possible to release tissue within a week, when theoretically it
 1098 would be classed as 'fresh'. The membranes can be applied to the defect with tissue glue (fibrin
 1099 glue, Tisseel®) or sutures. Lyophilized AM has been shown to have lower concentrations of
 1100 proteins/growth factors (Rodriguez-Ares et al., 2009). AM has many features that make it
 1101 extremely useful for the prevention and treatment of corneal ulceration (Tseng et al., 2004). Its
 1102 basement membrane is composed of collagen types IV and VII, laminin 1 and 5 and fibronectin
 1103 (Cooper et al., 2005). The laminin and fibronectin assist in epithelial cell adhesion and are
 1104 therefore useful in treatment of PEDs (Cameron et al., 1988; Nakagawa et al., 1990). The stroma
 1105 also contains multiple growth factors (EGF, TGF- α , KGF, HGF, bFGF, TGF- β 1, - β 2), anti-
 1106 angiogenic factors (thrombospondin-1 and collagen VIII), TIMPs (1,2,3 and 4) and anti-

1107 inflammatory factors (IL-1 receptor inhibitor and IL-10) that may help in the resolution of ulcers
 1108 and decrease scarring (Koizumi et al., 2000). The major use of AMT in corneal pathology is in
 1109 the management of neurotrophic ulcers (severe NK) and PEDs. Kruse et al. evaluated multilayer
 1110 AMT in neurotrophic ulcers that had failed after at least 4 weeks of conventional therapy with
 1111 lubrication, patching, or bandage contact lenses. They found that all the ulcers resolved at 4-5
 1112 weeks following AMT, but the surface layer of AMT disappeared faster than the ulcer healed,
 1113 and multiple layers were necessary to achieve resolution of the ulcer (Kruse et al., 1999). Chen et
 1114 al. performed a similar study on longstanding neurotrophic ulcers of various etiologies that had
 1115 failed conventional therapy (Chen et al., 2000). They found that 76% of the eyes had rapid
 1116 epithelial healing within 16 days. However, more than half of their patients also needed
 1117 adjunctive therapy with tarsorrhaphy, bandage contact lens, or bandage amniotic membrane,
 1118 reiterating that single layer AMT may not be sufficient for severe neurotrophic ulcers.

1119 Prokera™, which consists of an amniotic membrane clipped into a dual PMMA ring set,
 1120 has been used for the treatment of chronic ulcers. The advantage of this device is that it does not
 1121 need sutures for placement and can be easily slipped into the eye like a large scleral contact lens
 1122 (Suri et al., 2013). Other commercially available are Amnion (Bio-Tissue, Inc., Miami, FL),
 1123 fresh frozen, and Ambiodry2 (IOP Ophthalmics, Costa Mesa, CA), freeze-dried. A suspension of
 1124 homogenized amniotic membrane in BSS has been used topically in patients with ulcers
 1125 refractory to conventional therapy. Healing of all ulcers occurred by 28 days following
 1126 institution of therapy (Bonci et al., 2005).

1127 *10.3.5 Tissue adhesives*

1128 Tissue adhesives have been used for the closure of corneal defects and perforations for
 1129 many years (Bloomfield et al., 1963; Refojo et al., 1968). In the presence of a small perforation

1130 (less than 3mm) the application of tissue adhesive on the lesion, followed by the application of a
 1131 soft bandage contact lens or AMT is the procedure of choice. Larger defects require a
 1132 conjunctival flap or lamellar keratoplasty (Mantelli et al., 2015). Two basic types of adhesives
 1133 are used in ophthalmology, synthetic (cyanoacrylate) and biologic (fibrin glue) (Bhatia, 2006).
 1134 Cyanoacrylate polymerizes rapidly in the presence of water (tissue fluid) and also releases
 1135 formaldehyde during polymerisation. Formaldehyde contributes to its antibacterial activity
 1136 against most gram-positive organisms (de Almeida Manzano et al., 2006; Diaz-Valle et al.,
 1137 2003). It forms a rigid, impermeable plaque on the surface of the eye, which needs to be covered
 1138 with a bandage contact lens to offer protection and avoid pain and trauma to the upper lid. The
 1139 contact lens also prevents the glue being dislodged by lid movement. It remains in the eye long-
 1140 term, as it is not biodegradable. Multiple perforations or a single perforation that continues to
 1141 leak from the edge of the first patch of glue application, requires one or more overlapping further
 1142 applications (Fig. 176). When there is a perforation with iris prolapse, the double drape
 1143 technique can be used. The prolapsed iris is covered with a circular disc of plastic drape without
 1144 glue and this in turn is covered with a larger disc of plastic drape with cyanoacrylate glue. The
 1145 second disc adheres to the corneal tissue around the first disc, which prevents the glue from
 1146 directly adhering to the iris (Gandhewar et al., 2013). The epithelium usually grows under the
 1147 glue and healing of the defect usually dislodges the glue.

1148 Fibrin glue polymerizes relatively slowly and is therefore less effective in frank
 1149 perforations with a brisk leak. Fibrin is also rapidly degraded, but the addition of aprotinin
 1150 (antifibrinolytic agent) delays lysis for up to 10-14 days. Placement of a bandage contact lens
 1151 after fibrin glue application also helps to retard degradation possibly by preventing access of
 1152 polymorphonuclear cells and their proteases. The fibrin scaffold allows migration of

keratocytes/fibroblasts and myofibroblasts, which in turn lay down collagen and help close the defect. Fibrin glue carries a theoretical risk of disease transmission as it is derived from pooled plasma. The advantage of fibrin glue is the higher comfort level and the absence of toxic metabolites (Sharma et al., 2003).

10.3.6 Conjunctival Flap

A conjunctival flap may be indicated to prevent progression of the epithelial defect to perforation (Pushker et al., 2001). Total conjunctival flaps are more useful in patients with severe stromal damage and poor visual prognosis. Partial or bridge flaps may be used for small or peripheral ulcers. Conjunctival flaps have some disadvantages that include corneal perforation under the flap, flap retraction, poor reversibility and the need for an operating room. Despite the disadvantages, conjunctival flaps can be helpful because they halt the inflammatory process, and eliminate need for frequent instillation of medication.

The procedure of using a flap of bulbar conjunctiva to cover nonhealing corneal ulceration was first described by Trygve Gundersen in 1958 (Gundersen, 1958). Gundersen's flaps were frequently used for this purpose, but they fell into disfavor because they were difficult to fashion, especially in patients who had undergone multiple ocular surgeries, and they sometimes retracted. Other modalities for treating these conditions, such as disposable therapeutic contact lenses and AMT, were also much easier to use. However, in selected cases, conjunctival flaps may be superior, as they can replace an unhealthy stromal bed with healthy basal tissue on which epithelium can grow. In addition, they provide vessels and a blood supply to diseased cornea. These vessels aid in healing of resistant infections and provide serum-based growth factors. Vascularized structures are also very resistant to ulceration and perforation (Conn et al., 1980). The original flap procedure involved performing a 360° peritomy, debriding

the corneal epithelium completely, and mobilizing the superior conjunctiva to cover the entire cornea. Various modifications have been made to that original technique in an attempt to decrease complications and increase the success rate, especially the use of partial pedicle grafts (Alino et al., 1998; Khodadoust and Quinter, 2003; Sandinha et al., 2006). It is generally accepted that conjunctival flaps need to retain a pedicle to ensure continued supply of blood. This makes mobilization and advancement of conjunctiva on to the cornea difficult in cases where the underlying pathology for NK, such as chemical burns, affects the conjunctiva also. Dua et al. proposed use of a free autologous conjunctival graft from the opposite eye or from a distal surviving site in the same eye (Dua et al., 2012). The free graft covers the affected cornea in whole or part; the peripheral margin of the graft or at least part of it and the edge(s) sutured to viable tissue (with a blood supply intact). This allows blood vessels to connect with the vessels and in the graft that carry blood to the affected cornea, helping it heal. Other methods that have been tried for grafts to maintain globe integrity include buccal mucous membrane grafts, split thickness dermal grafts, and tenon's capsule grafts (Ma'luf and Awwad, 2005; Mauriello et al., 1988; Reim et al., 1992).

10.3.7 Corneal transplants

When all other options have failed to heal progressive corneal ulceration, a tectonic corneal transplant is often the last resort. Corneal transplants are preferably done as a planned procedure after the active ulceration has resolved and all inflammation has settled, though often it has to be performed in cases with impending perforation of perforated corneas. Risk of rejection and failure is greater with 'hot grafts' and grafts performed in background of NK are at high risk of failure (Jonas et al., 2001). However, tectonic grafts that are performed to preserve the structural integrity of the cornea have some advantages over other treatment modalities. The

vision is often better than that achieved with glue, amniotic membranes, or conjunctival flaps if the visual axis is involved (Killingsworth et al., 1993; Vanathi et al., 2002). Corneal grafts may be lamellar or penetrating. The advantage of lamellar transplant is that the anterior chamber is not entered in corneas that have not perforated. However, they are often technically challenging and may have poor visual outcomes (Soong et al., 2000). Jonas et al. compared the outcomes of penetrating keratoplasty in patients with corneal ulcers and patients with corneal scars from healed corneal ulcers (Jonas et al., 2001). They found that the visual outcomes were poorer and there were more episodes of rejection and loose sutures in the tectonic grafts. However, the visual outcomes were much better than with the lamellar transplants. Elective corneal transplantation for visual rehabilitation in patients with NK carries a high risk of failure. These patients have poor epithelial wound healing and are prone to inflammation. Both of these factors significantly increase the risk of melting, perforation and rejection.

A conjunctival flap is recommended when descemetocoele or perforation recurs despite previous corneal transplantation (Vasseneix et al., 2006). The Boston keratoprosthesis implantation has emerged as an effective modality for visual rehabilitation in such patients (Katzman and Jeng, 2014; Pavan-Langston and Dohlman, 2008).

10.3.8 Direct neurotisation

Direct neurotization of the cornea using the contralateral supraorbital and supratrochlear branches of the ophthalmic division of the trigeminal nerve has been performed for restoring the corneal sensitivity in patients with unilateral facial palsy and anesthetic cornea. Terzis et al (Terzis et al., 2009) described a novel surgical procedure in which donor nerve branches are inserted at the contralateral anesthetic corneal limbus for sensory neurotization. Use of the sural

nerve for this purpose has also been described (Bains et al., 2015; Elbaz et al., 2014). This surgical technique, although difficult to perform, preserves ocular anatomy and cosmesis and restores function. A step-ladder approach to the use of medical, non-surgical and surgical interventions in the management of NK is given in table 3.

1225

1226 11. Future Directions

Testing corneal sensitivity is key to recognition and diagnosis of NK. Corneal sensitivity testing is not routinely undertaken in clinical practice and is inadequately performed with the help of a cotton ~~whisp~~ or tissue paper rolled to a fine tapering end with bare fingers (unsterile). This, at best gives a qualitative estimate of the central cornea as it is usually performed in the central cornea ignoring the four quadrants. The Cochet Bonnet aesthesiometer gives a reasonable quantitative estimate of corneal sensitivity. Its nylon thread is re-usable, usually cleaned with a surgical wipe but is not sterile. The Belmonte aesthesiometer is a non-contact device; ~~more sophisticated and accurate~~ but ~~unwieldy and~~ for practical reasons is not widely used. As a result, NK remains an under-diagnosed condition. There is a strong need for a method or device that is clinically practical and easy to use in busy clinics, yet providing a quantitative (or semi quantitative) assesment. ~~Research is underway to produce a standardised clinical tool that is sterile, disposable, easy to use and give semi-quantitative assessment of corneal sensitivity. Such a device would be very desirable and should be available for trial in the next year or two.~~

Corneal hyperaesthesia is recognised as a feature of corneal pathology and may also be part of the process that eventually culminates in hypoaesthesia and complete loss of sensation. This can be associated with increased firing of existing nerves or abberant regeneration of nerves. There is

1243 no method available to test increased sensitivity. In future, as understanding of hyperaesthesia
1244 and methods of assessing it will become important.

1245 The pathophysiology of NK is ill-understood and often compounded by the pathophysiology
1246 of the causative underlying condition or agent. This makes for inadequate staging or grading of
1247 the condition and treatment strategies are difficult to target towards specific factors in the
1248 etiopathogenesis. In addition, interactions between disease processes and iatrogenic interventions
1249 make diagnosis and treatments even more difficult; therapeutic protocols lack standardization
1250 and duration of treatment remains unclear as recurrences may occur if treatment is tapered too
1251 early or in cases where the underlying condition cannot be cured. ~~Lack of functional innervation~~
1252 ~~and consequent deprivation of trophic environment increases risk of delayed or poor post~~
1253 ~~surgical wound healing, limiting surgical options for restoration of vision, in corneas affected by~~
1254 ~~NK. Nevertheless, an~~ Nevertheless, affection of the sensory nerves of the cornea is common to
1255 all stages/grades of NK. ~~Until recently and~~ there ~~was~~ no drug that addressed ~~ds~~ this factor. The
1256 ~~recent~~ advent of NGF with proven clinical efficacy through clinical trials offers a lot of promise.
1257 ~~and o~~ Other topically administered products that promote ~~nerve health and growth~~ epithelial
1258 healing, are in the pipeline. as therapeutic agents specifically aiming to restore effects of nerve
1259 ~~damage, offer promise.~~ These products should become available for clinical use in the near
1260 future leading to post marketing clinical trials, which in turn will establish the true potential of
1261 the products.

1262 Surgical neurotisation of the cornea with nerve grafts is an elaborate procedure, still in its
1263 infancy but with exciting and promising possibilities. The foreseeable future will see
1264 improvement in surgical techniques and improved outcomes making the surgery available to
1265 more patients by a greater number of trained surgeons. High resolution in vivo confocal

1266 microscopy imaging of the cornea following neurotisation or treatment with rhNGF or Netrin-
 1267 I should allow direct visualisation of the new nerves sprouting from the transplanted trunks.

1268 Patients with NK manifest local (eye specific) symptoms, general health and social and
 1269 psychological problems. Due to duration of the disease, its potential visual impact and the burden
 1270 of the range of treatment options, quality of life can be severely affected by NK. There is a lack
 1271 of a specific NK related tool to accurately assess quality of life (QoL) in these individuals. The
 1272 main objectives of future therapies will thus be to tackle all these complex issues to heal the
 1273 cornea, to prevent or reverse vision impairment and improve quality of life of NK patients.

1274

1275 **12. Acknowledgements**

1276 This research did not receive any specific grant from funding agencies in the public,
 1277 commercial, or not-for-profit sectors.

1278

1279 **13. Funding support: None**

1280

1281 **14. References**

- 1282 DEWS report 2007. The epidemiology of dry eye disease: report of the Epidemiology
 1283 Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 5, 93-107.
- 1284 [Abdul-Hussien, H., Hanemaaijer, R., Verheijen, J.H., van Bockel, J.H., Geelkerken, R.H.,](#)
 1285 [Lindeman, J.H., 2009. Doxycycline therapy for abdominal aneurysm: Improved proteolytic](#)
 1286 [balance through reduced neutrophil content. J Vasc Surg 49, 741-9.](#)
- 1287 Acosta, M.C., Luna, C., Quirce, S., Belmonte, C., Gallar, J., 2013. Changes in sensory activity of
 1288 ocular surface sensory nerves during allergic keratoconjunctivitis. Pain 154, 2353-2362.

- 1289 Alamri, A., Bron, R., Brock, J.A., Ivanusic, J.J., 2015. Transient receptor potential cation
1290 channel subfamily V member 1 expressing corneal sensory neurons can be subdivided into at
1291 least three subpopulations. *Front Neuroanat* 9, 71.
- 1292 Al-Aqaba, M., Alomar, T., Lowe, J., Dua, H.S., 2011a. Corneal nerve aberrations in bullous
1293 keratopathy. *Am J Ophthalmol* 151, 840-849.
- 1294 Al-Aqaba, M.A., Faraj, L., Fares, U., Otri, A.M., Dua, H.S., 2011b. The morphologic
1295 characteristics of corneal nerves in advanced keratoconus as evaluated by acetylcholinesterase
1296 technique. *Am J Ophthalmol* 152, 364-376 e361.
- 1297 Al-Aqaba, M.A., Fares, U., Suleman, H., Lowe, J., Dua, H.S., 2010. Architecture and
1298 distribution of human corneal nerves. *Br J Ophthalmol* 94, 784-789.
- 1299 Al-Aqaba, M.A., Otri, A.M., Fares, U., Miri, A., Dua, H.S., 2012. Organization of the
1300 regenerated nerves in human corneal grafts. *Am J Ophthalmol* 153, 29-37 e24.
- 1301 [Albietz, J.M., Lenton L.M., McLennan, S.G., 2005. Dry eye after LASIK: comparison of](#)
1302 [outcomes for Asian and Caucasian eyes. *Clin Exp Optom* 88, 89-96.](#)
- 1303 Ali, Z., Insler, M.S., 1986. A comparison of therapeutic bandage lenses, tarsorrhaphy, and
1304 antibiotic and hypertonic saline on corneal epithelial wound healing. *Ann Ophthalmol* 18, 22-24.
- 1305 Alino, A.M., Perry, H.D., Kanellopoulos, A.J., Donnenfeld, E.D., Rahn, E.K., 1998.
1306 Conjunctival flaps. *Ophthalmology* 105, 1120-1123.
- 1307 Alio, J.L., Pastor, S., Ruiz-Colecha, J., Rodriguez, A., Artola, A., 2007. Treatment of ocular
1308 surface syndrome after LASIK with autologous platelet-rich plasma. *J Refract Surg* 23, 617-619.
- 1309 [Alio, J.L., Rodriguez, A.E., Abdelghany, A.A., Oliveira, R.F., 2017. Autologous Platelet-Rich](#)
1310 [Plasma Eye Drops for the Treatment of Post-LASIK Chronic Ocular Surface Syndrome. *J*](#)
1311 [*Ophthalmol* 2017, 2457620.](#)
- 1312 Allen, V.D., Malinovsky, V., 2003. Management of neurotrophic keratopathy. *Cont Lens*
1313 *Anterior Eye* 26, 161-165.
- 1314 Alper, M.G., 1975. The anesthetic eye: an investigation of changes in the anterior ocular segment
1315 of the monkey caused by interrupting the trigeminal nerve at various levels along its course.
1316 *Trans Am Ophthalmol Soc* 73, 323-365.
- 1317 Ambrosio, R., Jr., Tervo, T., Wilson, S.E., 2008. LASIK-associated dry eye and neurotrophic
1318 epitheliopathy: pathophysiology and strategies for prevention and treatment. *J Refract Surg* 24,
1319 396-407.
- 1320 [Anitua, E., Muruzabal, F., de la Fuente, M., Merayo, J., Durán, J., Orive, G., 2016. Plasma Rich](#)
1321 [in Growth Factors for the Treatment of Ocular Surface Diseases. *Curr Eye Res* 41, 875-82.](#)
- 1322 Aragona, P., Rolando, M., 2013. Towards a dynamic customised therapy for ocular surface
1323 dysfunctions. *Br J Ophthalmol* 97, 955-960.

- 1324 [Araki, K., Ohashi, Y., Kinoshita, S., Hayashi, K., Kuwayama, Y., Tano, Y., 1994. Epithelial](#)
1325 [wound healing in the denervated cornea. Curr Eye Res13, 203-211.](#)
- 1326 Avisar, R., Deutsch, D., Savir, H., 1988. Corneal calcification in dry eye disorders associated
1327 with retinoic acid therapy. Am J Ophthalmol 106, 753-755.
- 1328 [Ayaki, M., Iwasawa, A., Niwano, Y., 2012. In vitro assessment of the cytotoxicity of six topical](#)
1329 [antibiotics to four cultured ocular surface cell lines. Biocontrol Sci 17, 93-9.](#)
- 1330 Azari, A.A., Rapuano, C.J., 2015. Autologous serum eye drops for the treatment of ocular
1331 surface disease. Eye Contact Lens 41, 133-140.
- 1332 Azuara-Blanco, A., Pillai, C.T., Dua, H.S., 1999. Amniotic membrane transplantation for ocular
1333 surface reconstruction. Br J Ophthalmol 83, 399-402.
- 1334 [Azuma, M., Yabuta, C., Fraunfelder, F.W., Shearer, T.R., 2014. Dry eye in LASIK patients](#)
1335 [BMC Research Notes 7, 420. Baenninger, P.B., Dinah, C., Figueiredo, F.C., 2014. Survey on](#)
1336 [Bandage Contact Lens Practice in the United Kingdom. 5:325. J Clin Exp Ophthalmol 5, 325.](#)
- 1337 Bains, R.D., Elbaz, U., Zuker, R.M., Ali, A., Borschel, G.H., 2015. Corneal neurotization from
1338 the supratrochlear nerve with sural nerve grafts: a minimally invasive approach. Plast Reconstr
1339 Surg 135, 397e-400e.
- 1340 Bandell, M., Story, G.M., Hwang, S.W., Viswanath, V., Eid, S.R., Petrus, M.J., Earley, T.J.,
1341 Patapoutian, A., 2004. Noxious cold ion channel TRPA1 is activated by pungent compounds and
1342 bradykinin. Neuron 41, 849-857.
- 1343 Banerjee, P.J., Chandra, A., Sullivan, P.M., Charteris, D.G., 2014. Neurotrophic corneal
1344 ulceration after retinal detachment surgery with retinectomy and endolaser: a case series. JAMA
1345 ophthalmology 132, 750-752.
- 1346 Baudouin, C., Aragona, P., Messmer, E.M., Tomlinson, A., Calonge, M., Boboridis, K.G.,
1347 Akova, Y.A., Geerling, G., Labetoulle, M., Rolando, M., 2013. Role of hyperosmolarity in the
1348 pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting.
1349 Ocul Surf 11, 246-258.
- 1350 Baudouin, C., Labbe, A., Liang, H., Pauly, A., Brignole-Baudouin, F., 2010. Preservatives in
1351 eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 29, 312-334.
- 1352 Bautista, D.M., Pellegrino, M., Tsunozaki, M., 2013. TRPA1: A gatekeeper for inflammation.
1353 Annu Rev Physiol 75, 181-200.
- 1354 Baxter, S.A., Laibson, P.R., 2004. Punctal plugs in the management of dry eyes. Ocul Surf 2,
1355 255-265.
- 1356 Belmonte, C., Acosta, M.C., Gallar, J., 2004a. Neural basis of sensation in intact and injured
1357 corneas. Exp Eye Res 78, 513-525.

- 1358 Belmonte, C., Acosta, M.C., Schmelz, M., Gallar, J., 1999. Measurement of corneal sensitivity to
1359 mechanical and chemical stimulation with a CO₂ esthesiometer. *Invest Ophthalmol Vis Sci* 40,
1360 513-519.
- 1361 Belmonte, C., Aracil, A., Acosta, M.C., Luna, C., Gallar, J., 2004b. Nerves and sensations from
1362 the eye surface. *Ocul Surf* 2, 248-253.
- 1363 Belmonte, C., Brock, J.A., Viana, F., 2009. Converting cold into pain. *Exp Brain Res* 196, 13-30.
- 1364 Belmonte, C., Gallar, J., 2011. Cold thermoreceptors, unexpected players in tear production and
1365 ocular dryness sensations. *Invest Ophthalmol Vis Sci* 52, 3888-3892.
- 1366 Belmonte, C., Gallar, J., Pozo, M.A., Rebollo, I., 1991. Excitation by irritant chemical
1367 substances of sensory afferent units in the cat's cornea. *J Physiol* 437, 709-725.
- 1368 Belmonte, C., Giraldez, F., 1981. Responses of cat corneal sensory receptors to mechanical and
1369 thermal stimulation. *J Physiol* 321, 355-368.
- 1370 Belmonte, C., Nichols, J.J., Cox, S.M., Brock, J.A., Begley, C.G., Bereiter, D.A., Dartt, D.A.,
1371 Galor, A., Hamrah, P., Ivanusic, J.J., Jacobs, D.S., McNamara, N.A., Rosenblatt, M.I., Stapleton,
1372 F., Wolffsohn, J.S., 2017. TFOS DEWS II pain and sensation report. *Ocul Surf* 15, 404-437.
- 1373 Benitez del Castillo, J.M., Wasfy, M.A., Fernandez, C., Garcia-Sanchez, J., 2004. An in vivo
1374 confocal masked study on corneal epithelium and subbasal nerves in patients with dry eye. *Invest*
1375 *Ophthalmol Vis Sci* 45, 3030-3035.
- 1376 Bentivoglio, A.R., Bressman, S.B., Cassetta, E., Carretta, D., Tonali, P., Albanese, A., 1997.
1377 Analysis of blink rate patterns in normal subjects. *Mov Disord* 12, 1028-1034.
- 1378 Bernauer, W., Thiel, M.A., Kurrer, M., Heiligenhaus, A., Rentsch, K.M., Schmitt, A., Heinz, C.,
1379 Yanar, A., 2006a. Corneal calcification following intensified treatment with sodium hyaluronate
1380 artificial tears. *Br J Ophthalmol* 90, 285-288.
- 1381 Bernauer, W., Thiel, M.A., Langenauer, U.M., Rentsch, K.M., 2006b. Phosphate concentration
1382 in artificial tears. *Graefes Arch Clin Exp Ophthalmol* 244, 1010-1014.
- 1383 Beuerman, R.W., Klyce, S., Kooner, S., Tanelian, D., Rosza, A., 1983. Dimensional analysis of
1384 rabbit ciliary nerve [abstract]. *Investigative Ophthalmology & Visual Science* 24 (suppl.), 261.
- 1385 Beuerman, R.W., Schimmelpfennig, B., 1980. Sensory denervation of the rabbit cornea affects
1386 epithelial properties. *Exp Neurol* 69, 196-201.
- 1387 Bhatia, S.S., 2006. Ocular surface sealants and adhesives. *Ocul Surf* 4, 146-154.
- 1388 Bhatti, M.T., Patel, R., 2005. Neuro-ophthalmic considerations in trigeminal neuralgia and its
1389 surgical treatment. *Curr Opin Ophthalmol* 16, 334-340.
- 1390 Bloomfield, S., Barnert, A.H., Kanter, P.D., 1963. The use of Eastman 910 monomer as an
1391 adhesive in ocular surgery. I. Biologic effects on ocular tissues. *Am J Ophthalmol* 55, 742-748.

- 1392 Bonci, P.O., Bonci, P.A., Lia, A., 2005. Suspension made with amniotic membrane: Clinical
1393 trial. *Eur J Ophthalmol* 15, 441-445.
- 1394 Bonini, S., Lambiase, A., Rama, P., Caprioglio, G., Aloe, L., 2000. Topical treatment with nerve
1395 growth factor for neurotrophic keratitis. *Ophthalmology* 107, 1347-1351; discussion 1351-1342.
- 1396 Bonini, S., Rama, P., Olzi, D., Lambiase, A., 2003. Neurotrophic keratitis. *Eye (Lond)* 17, 989-
1397 995.
- 1398 Bron, R., Wood, R.J., Brock, J.A., Ivanusic, J.J., 2014. Piezo2 expression in corneal afferent
1399 neurons. *J Comp Neurol* 522, 2967-2979.
- 1400 Callejo, G., Castellanos, A., Castany, M., Gual, A., Luna, C., Acosta, M.C., Gallar, J., Giblin,
1401 J.P., Gasull, X., 2015. Acid-sensing ion channels detect moderate acidifications to induce ocular
1402 pain. *Pain* 156, 483-495.
- 1403 Cameron, J.D., Hagen, S.T., Waterfield, R.R., Furcht, L.T., 1988. Effects of matrix proteins on
1404 rabbit corneal epithelial cell adhesion and migration. *Curr Eye Res* 7, 293-301.
- 1405 Carr, R.W., Pianova, S., Fernandez, J., Fallon, J.B., Belmonte, C., Brock, J.A., 2003. Effects of
1406 heating and cooling on nerve terminal impulses recorded from cold-sensitive receptors in the
1407 guinea-pig cornea. *J Gen Physiol* 121, 427-439.
- 1408 Caterina, M.J., Schumacher, M.A., Tominaga, M., Rosen, T.A., Levine, J.D., Julius, D., 1997.
1409 The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature* 389, 816-824.
- 1410 [Cavalcanti, B.M., Cruzat, A., Sahin, A., Pavan-Langston, D., Samayoa, E., Hamrah, P., 2018. In](#)
1411 [vivo confocal microscopy detects bilateral changes of corneal immune cells and nerves in](#)
1412 [unilateral herpes zoster ophthalmicus. The Ocular Surface 16, 101-11.](#)
- 1413 Chan, K.Y., Haschke, R.H., 1981. Action of a trophic factor(s) from rabbit corneal epithelial
1414 culture on dissociated trigeminal neurons. *J Neurosci* 1, 1155-1162.
- 1415 [Chao, C., Golebiowski B., Stapleton, F., 2014. The role of corneal innervation in LASIK induced](#)
1416 [neuropathic dry eye. Ocul Surf 12, 32-45.](#)
- 1417 Chao, W., Benitez Del Castillo, J., Dana, R., Geerling, G., Mantelli, F., Massaro-Giordano, G.,
1418 Rama, P., 2017. Healing of persistent epithelial defects or corneal ulcer by recombinant human
1419 nerve growth factor eye drops in patients with stage 2 or 3 neurotrophic keratitis [abstract]. SOE
1420 2017 Congress, European Society of Ophthalmology, Barcelona, Spain.
- 1421 Chen, H.J., Pires, R.T., Tseng, S.C., 2000. Amniotic membrane transplantation for severe
1422 neurotrophic corneal ulcers. *Br J Ophthalmol* 84, 826-833.
- 1423 Chen, L., Wei, R.H., Tan, D.T., Beuerman, R.W., Li, W., Zhao, S., 2014. Nerve growth factor
1424 expression and nerve regeneration in monkey corneas after LASIK. *J Refract Surg* 30, 134-139.
- 1425 Chotikavanich, S., de Paiva, C.S., Li de, Q., Chen, J.J., Bian, F., Farley, W.J., Pflugfelder, S.C.,
1426 2009. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in
1427 dysfunctional tear syndrome. *Invest Ophthalmol Vis Sci* 50, 3203-3209.

- 1428 Claerhout, I., Kestelyn, P., Meire, F., Remon, J.P., Decaestecker, T., Van Bocxlaer, J., 2003.
1429 Corneal deposits after the topical use of ofloxacin in two children with vernal
1430 keratoconjunctivitis. *Br J Ophthalmol* 87, 646.
- 1431 Clare, G., Suleman, H., Bunce, C., Dua, H., 2012. Amniotic membrane transplantation for acute
1432 ocular burns. *Cochrane Database Syst Rev*, CD009379.
- 1433 Clark, A.F., 2014. A useful mouse model of glucocorticoid-induced ocular hypertension. *Invest*
1434 *Ophthalmol Vis Sci* 55, 4934.
- 1435 Cohen, E.J., 1999. Punctal occlusion. *Arch Ophthalmol* 117, 389-390.
- 1436 Conn, H., Berman, M., Kenyon, K., Langer, R., Gage, J., 1980. Stromal vascularization prevents
1437 corneal ulceration. *Invest Ophthalmol Vis Sci* 19, 362-370.
- 1438 Cooper, L.J., Kinoshita, S., German, M., Koizumi, N., Nakamura, T., Fullwood, N.J., 2005. An
1439 investigation into the composition of amniotic membrane used for ocular surface reconstruction.
1440 *Cornea* 24, 722-729.
- 1441 Cosar, C.B., Cohen, E.J., Rapuano, C.J., Maus, M., Penne, R.P., Flanagan, J.C., Laibson, P.R.,
1442 2001. Tarsorrhaphy: clinical experience from a cornea practice. *Cornea* 20, 787-791.
- 1443 Cottrell, P., Ahmed, S., James, C., Hodson, J., McDonnell, P.J., Rauz, S., Williams, G.P., 2014.
1444 Neuron J is a rapid and reliable open source tool for evaluating corneal nerve density in herpes
1445 simplex keratitis. *Invest Ophthalmol Vis Sci* 55, 7312-7320.
- 1446 Dart, J., 2003. Corneal toxicity: the epithelium and stroma in iatrogenic and factitious disease.
1447 *Eye (Lond)* 17, 886-892.
- 1448 Davis, J.B., Gray, J., Gunthorpe, M.J., Hatcher, J.P., Davey, P.T., Overend, P., Harries, M.H.,
1449 Latcham, J., Clapham, C., Atkinson, K., Hughes, S.A., Rance, K., Grau, E., Harper, A.J., Pugh,
1450 P.L., Rogers, D.C., Bingham, S., Randall, A., Sheardown, S.A., 2000. Vanilloid receptor-1 is
1451 essential for inflammatory thermal hyperalgesia. *Nature* 405, 183-187.
- 1452 de Almeida Manzano, R.P., Naufal, S.C., Hida, R.Y., Guarnieri, L.O., Nishiwaki-Dantas, M.C.,
1453 2006. Antibacterial analysis in vitro of ethyl-cyanoacrylate against ocular pathogens. *Cornea* 25,
1454 350-351.
- 1455 De Haas, E.H., 1962. Desiccation of cornea and conjunctiva after sensory denervation:
1456 Significance of desiccation for pathogenesis of neuroparalytic keratitis. *Archives of*
1457 *Ophthalmology* 67, 439-452.
- 1458 DeMartelaere, S.L., Blaydon, S.M., Tovilla-Canales, J.L., Shore, J.W., 2006. A permanent and
1459 reversible procedure to block tear drainage for the treatment of dry eye. *Ophthal Plast Reconstr*
1460 *Surg* 22, 352-355.
- 1461 Dhillon, V.K., Elalfy, M.S., Al-Aqaba, M., Gupta, A., Basu, S., Dua, H.S., 2016. Corneal
1462 hypoesthesia with normal sub-basal nerve density following surgery for trigeminal neuralgia.
1463 *Acta Ophthalmol* 94, e6-10.

- 1464 Di, G., Qi, X., Zhao, X., Zhang, S., Danielson, P., Zhou, Q., 2017. Corneal epithelium-derived
1465 neurotrophic factors promote nerve regeneration. *Invest Ophthalmol Vis Sci* 58, 4695-4702.
- 1466 Diaz-Valle, D., Benitez del Castillo Sanchez, J.M., Diaz Rodriguez, E., Toledano Fernandez, N.,
1467 Arteaga Sanchez, A., Sayagues Gomez, O., 2003. [Neurotrophic keratopathy management with
1468 cyanoacrylate tarsorrhaphy and autologous serum]. *Arch Soc Esp Oftalmol* 78, 119-122.
- 1469 Dua, H.S., Elalfy, M.S., Said, D.G., 2014. Key questions on visual problems in older patients,
1470 Pulse [http://www.pulsetoday.co.uk/clinical/key-questions-on-visual-problems-in-older-patients-
1471 15-cpd-hours/20008664.article](http://www.pulsetoday.co.uk/clinical/key-questions-on-visual-problems-in-older-patients-15-cpd-hours/20008664.article) (accessed 20 November 2017).
- 1472 Dua, H.S., Gomes, J.A., King, A.J., Maharajan, V.S., 2004. The amniotic membrane in
1473 ophthalmology. *Surv Ophthalmol* 49, 51-77.
- 1474 Dua, H.S., Miri, A., Faraj, L.A., Said, D.G., 2012. Free autologous conjunctival grafts.
1475 *Ophthalmology* 119, 2189-2189 e2182.
- 1476 [Dua, H.S., Otri, M., Said, D.G., Faraj, L.A., 2012. The 'up-down' sign of acute ocular surface
1477 drug toxicity. *Br J Ophthalmol* 96, 1439-40.](#)
- 1478 Dubler, A., 1884. Über neuritis bei Herpes Zoster. *Virchows Arch A Pathol Anat* 96, 195.
- 1479 Duke-Elder, W.S., Leigh, A.G., 1965. Neurotrophic keratitis, in: Duke-Elder, W.S. (Ed.), *System
1480 of Ophthalmology. Volume 8, Part 2: Diseases of the Outer Eye*. Kimpton/Mosby, London, pp.
1481 803-806.
- 1482 Dworkin, R.H., Johnson, R.W., Breuer, J., Gnann, J.W., Levin, M.J., Backonja, M., Betts, R.F.,
1483 Gershon, A.A., Haanpaa, M.L., McKendrick, M.W., Nurmikko, T.J., Oaklander, A.L., Oxman,
1484 M.N., Pavan-Langston, D., Petersen, K.L., Rowbotham, M.C., Schmader, K.E., Stacey, B.R.,
1485 Tyring, S.K., van Wijck, A.J., Wallace, M.S., Wassilew, S.W., Whitley, R.J., 2007.
1486 Recommendations for the management of herpes zoster. *Clin Infect Dis* 44 Suppl 1, S1-26.
- 1487 [Erdem, E., Yagmur, M., Harbiyeli, I., Taylan-Sekeroglu, H., Ersoz R., 2014. Umbilical cord
1488 blood serum therapy for the management of persistent corneal epithelial defects. 7, 807-10.](#)
- 1489 Ehinger, B., 1971. A comparative study of the adrenergic nerves to the anterior eye segment of
1490 some primates. *Z Zellforsch Mikrosk Anat* 116, 157-177.
- 1491 Elbaz, U., Bains, R., Zuker, R.M., Borschel, G.H., Ali, A., 2014. Restoration of corneal sensation
1492 with regional nerve transfers and nerve grafts: a new approach to a difficult problem. *JAMA
1493 Ophthalmol* 132, 1289-1295.
- 1494 European Medicines Agency, 2017. Oxervate (cenegermin): summary of the European public
1495 assessment report (EPAR),
1496 [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004209/huma
1497 n_med_002135.jsp](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004209/human_med_002135.jsp) (accessed 20 November 2017).
- 1498 Faraj, L.A., Said, D.G., Al-Aqaba, M., Otri, A.M., Dua, H.S., 2016. Clinical evaluation and
1499 characterisation of corneal vascularisation. *Br J Ophthalmol* 100, 315-322.

- 1500 [Feiz, V., Oberg, T.J., Kurz, C.J., Mamalis, N., Moshirfar, M., 2009. Nepafenac-associated](#)
1501 [bilateral corneal melt after photorefractive keratectomy. Cornea 28, 948-50.](#)
- 1502 Felipe, C.D., Gonzalez, G.G., Gallar, J., Belmonte, C., 1999. Quantification and
1503 immunocytochemical characteristics of trigeminal ganglion neurons projecting to the cornea:
1504 effect of corneal wounding. Eur J Pain 3, 31-39.
- 1505 Fini, M.E., Cook, J.R., Mohan, R., 1998. Proteolytic mechanisms in corneal ulceration and
1506 repair. Arch Dermatol Res 290 Suppl, S12-23.
- 1507 Fini, M.E., Girard, M.T., Matsubara, M., 1992. Collagenolytic/gelatinolytic enzymes in corneal
1508 wound healing. Acta Ophthalmol Suppl, 26-33.
- 1509 Fukushima, A., Ohashi, Y., Ebihara, N., Uchio, E., Okamoto, S., Kumagai, N., Shoji, J.,
1510 Takamura, E., Nakagawa, Y., Namba, K., Fujishima, H., Miyazaki, D., 2014. Therapeutic effects
1511 of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or
1512 corneal involvement. Br J Ophthalmol 98, 1023-1027.
- 1513 Gallar, J., Pozo, M.A., Tuckett, R.P., Belmonte, C., 1993. Response of sensory units with
1514 unmyelinated fibres to mechanical, thermal and chemical stimulation of the cat's cornea. J
1515 Physiol 468, 609-622.
- 1516 Gandhewar, J., Savant, V., Prydal, J., Dua, H., 2013. Double drape tectonic patch with
1517 cyanoacrylate glue in the management of corneal perforation with iris incarceration. Cornea 32,
1518 e137-138.
- 1519 Garcia-Hirschfeld, J., Lopez-Briones, L.G., Belmonte, C., 1994. Neurotrophic influences on
1520 corneal epithelial cells. Exp Eye Res 59, 597-605.
- 1521 Garrett, Q., Simmons, P.A., Xu, S., Vehige, J., Zhao, Z., Ehrmann, K., Willcox, M., 2007.
1522 Carboxymethylcellulose binds to human corneal epithelial cells and is a modulator of corneal
1523 epithelial wound healing. Invest Ophthalmol Vis Sci 48, 1559-1567.
- 1524 [Gaynes, B.I., Fiscella, R., 2001. Topical nonsteroidal anti-inflammatory drugs for ophthalmic](#)
1525 [use: a safety review. Drug Saf 25, 233-50.](#)
- 1526 Geerling, G., Daniels, J.T., Dart, J.K., Cree, I.A., Khaw, P.T., 2001. Toxicity of natural tear
1527 substitutes in a fully defined culture model of human corneal epithelial cells. Invest Ophthalmol
1528 Vis Sci 42, 948-956.
- 1529 Geerling, G., Joussen, A.M., Daniels, J.T., Mulholland, B., Khaw, P.T., Dart, J.K., 1999. Matrix
1530 metalloproteinases in sterile corneal melts. Ann N Y Acad Sci 878, 571-574.
- 1531 Geerling, G., Tauber, J., Baudouin, C., Goto, E., Matsumoto, Y., O'Brien, T., Rolando, M.,
1532 Tsubota, K., Nichols, K.K., 2011. The international workshop on meibomian gland dysfunction:
1533 report of the subcommittee on management and treatment of meibomian gland dysfunction.
1534 Invest Ophthalmol Vis Sci 52, 2050-2064.

- 1535 Gilbard, J.P., Rossi, S.R., 1990. Tear film and ocular surface changes in a rabbit model of
1536 neurotrophic keratitis. *Ophthalmology* 97, 308-312.
- 1537 Gipson, I.K., 2007. The ocular surface: the challenge to enable and protect vision: the
1538 Friedenwald lecture. *Invest Ophthalmol Vis Sci* 48, 4390; 4391-4398.
- 1539 Golebiowski, B., Papas, E., Stapleton, F., 2011. Assessing the sensory function of the ocular
1540 surface: implications of use of a non-contact air jet aesthesiometer versus the Cochet-Bonnet
1541 aesthesiometer. *Exp Eye Res* 92, 408-413.
- 1542 Gomes, J.A., Amankwah, R., Powell-Richards, A., Dua, H.S., 2004. Sodium hyaluronate
1543 (hyaluronic acid) promotes migration of human corneal epithelial cells in vitro. *Br J Ophthalmol*
1544 88, 821-825.
- 1545 Gomes, J.A., Romano, A., Santos, M.S., Dua, H.S., 2005. Amniotic membrane use in
1546 ophthalmology. *Curr Opin Ophthalmol* 16, 233-240.
- 1547 Gomes, J.A.P., Azar, D.T., Baudouin, C., Efron, N., Hirayama, M., Horwath-Winter, J., Kim, T.,
1548 Mehta, J.S., Messmer, E.M., Pepose, J.S., Sangwan, V.S., Weiner, A.L., Wilson, S.E.,
1549 Wolffsohn, J.S., 2017. TFOS DEWS II iatrogenic report. *Ocul Surf* 15, 511-538.
- 1550 Graham, R.H., 2016. Neurotrophic keratopathy. Medscape
1551 <https://emedicine.medscape.com/article/1194889-overview> (accessed 20 November 2017).
- 1552 Gris, O., Guell, J.L., Lopez-Navidad, A., Caballero, F., Del Campo, Z., 1999. Application of the
1553 amniotic membrane in ocular surface pathology. *Ann Transplant* 4, 82-84.
- 1554 Guerra, M., Marques, S., Gil, J.Q., Campos, J., Ramos, P., Rosa, A.M., Quadrado, M.J., Murta,
1555 J.N., 2017. Neurotrophic Keratopathy: Therapeutic Approach Using a Novel Matrix
1556 Regenerating Agent. *J Ocul Pharmacol Ther* 33, 662-669.
- 1557 [Guidera, A.C., Luchs, J.L., Udell, I.J., 2001. Keratitis, ulceration, and perforation associated with](#)
1558 [topical nonsteroidal anti-inflammatory drugs. *Ophthalmology* 108, 936-44.](#)
- 1559 Gundersen, T., 1958. Conjunctival flaps in the treatment of corneal disease with reference to a
1560 new technique of application. *AMA Arch Ophthalmol* 60, 880-888.
- 1561 Guo, A., Vulchanova, L., Wang, J., Li, X., Elde, R., 1999. Immunocytochemical localization of
1562 the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4
1563 binding sites. *Eur J Neurosci* 11, 946-958.
- 1564 Guzey, M., Ozardali, I., Kilic, A., Basar, E., Dogan, Z., Satıcı, A., Karadede, S., 2001. The
1565 treatment of severe trachomatous dry eye with canalicular silicone plugs. *Eye (Lond)* 15, 297-
1566 303.
- 1567 [Hahn, J.N., Kaushik, D.K., Mishra, M.K., Wang, J., Silva, C., Yong, V.W., 2016. Impact of](#)
1568 [minocycline on extracellular matrix metalloproteinase inducer, a factor implicated in multiple](#)
1569 [sclerosis immunopathogenesis. *J Immunol* 197, 3850-60.](#)

- 1570 [Hamrah, P., Cruzat, A., Dastjerdi, M.H., Prüss, H., Zheng, L., Shahatit, B.M., Bayhan, H.A.,](#)
 1571 [Dana, R., Pavan-Langston, D., 2103. Unilateral herpes zoster ophthalmicus results in bilateral](#)
 1572 [corneal nerve alteration: an in vivo confocal microscopy study. Ophthalmology, 120:40-7.](#)
- 1573 [Hamrah, P., Cruzat, A., Dastjerdi, M.H., Zheng, L., Shahatit, B.M., Bayhan, H.A., Dana, R.,](#)
 1574 [Pavan-Langston, D., 2010. Corneal sensation and subbasal nerve alterations in patients with](#)
 1575 [herpes simplex keratitis: an in vivo confocal microscopy study. Ophthalmology 117, 1930-6.](#)
- 1576 Hartwig, D., Harloff, S., Liu, L., Schlenke, P., Wedel, T., Geerling, G., 2004. Epitheliotropic
 1577 capacity of a growth factor preparation produced from platelet concentrates on corneal epithelial
 1578 cells: a potential agent for the treatment of ocular surface defects? Transfusion 44, 1724-1731.
- 1579 Hartwig, D., Herminghaus, P., Wedel, T., Liu, L., Schlenke, P., Dibbelt, L., Geerling, G., 2005.
 1580 Topical treatment of ocular surface defects: comparison of the epitheliotropic capacity of fresh
 1581 frozen plasma and serum on corneal epithelial cells in an in vitro cell culture model. Transfus
 1582 Med 15, 107-113.
- 1583 Heigle, T.J., Pflugfelder, S.C., 1996. Aqueous tear production in patients with neurotrophic
 1584 keratitis. Cornea 15, 135-138.
- 1585 Hosoi, J., Murphy, G.F., Egan, C.L., Lerner, E.A., Grabbe, S., Asahina, A., Granstein, R.D.,
 1586 1993. Regulation of Langerhans cell function by nerves containing calcitonin gene-related
 1587 peptide. Nature 363, 159-163.
- 1588 Hutnik, C.M., Probst, L.E., 1998. Argon laser punctal therapy versus thermal cautery for the
 1589 treatment of aqueous deficiency dry eye syndrome. Can J Ophthalmol 33, 365-372.
- 1590 [Jabbarvand, M., Hashemian, H., Khodaparast, M., Rafatnejad, A., Beheshtnejad, A., Salami, A.,](#)
 1591 [2015. Do unilateral herpetic stromal keratitis and neurotrophic ulcers cause bilateral dry eye?](#)
 1592 [Cornea 34, 768-72.](#)
- 1593 Iaccheri, B., Torroni, G., Cagini, C., Fiore, T., Cerquaglia, A., Lupidi, M., Cillino, S., Dua, H.S.,
 1594 2017. Corneal confocal scanning laser microscopy in patients with dry eye disease treated with
 1595 topical cyclosporine. Eye (Lond) 31, 788-794.
- 1596 Jonas, J.B., Rank, R.M., Budde, W.M., 2001. Tectonic sclerokeratoplasty and tectonic
 1597 penetrating keratoplasty as treatment for perforated or predecemetal corneal ulcers. Am J
 1598 Ophthalmol 132, 14-18.
- 1599 Joseph, A., Dua, H.S., King, A.J., 2001. Failure of amniotic membrane transplantation in the
 1600 treatment of acute ocular burns. Br J Ophthalmol 85, 1065-1069.
- 1601 Kangari, H., Eftekhari, M.H., Sardari, S., Hashemi, H., Salamzadeh, J., Ghassemi-Broumand,
 1602 M., Khabazkhoob, M., 2013. Short-term consumption of oral omega-3 and dry eye syndrome.
 1603 Ophthalmology 120, 2191-2196.
- 1604 Katzman, L.R., Jeng, B.H., 2014. Management strategies for persistent epithelial defects of the
 1605 cornea. Saudi J Ophthalmol 28, 168-172.

- 1606 Khodadoust, A., Quinter, A.P., 2003. Microsurgical approach to the conjunctival flap. Arch
1607 Ophthalmol 121, 1189-1193.
- 1608 Khokhar, S., Natung, T., Sony, P., Sharma, N., Agarwal, N., Vajpayee, R.B., 2005. Amniotic
1609 membrane transplantation in refractory neurotrophic corneal ulcers: a randomized, controlled
1610 clinical trial. Cornea 24, 654-660.
- 1611 Kiiski, V., Remitz, A., Reitamo, S., Mandelin, J., Kari, O., 2014. Long-term safety of topical
1612 pimecrolimus and topical tacrolimus in atopic blepharoconjunctivitis. JAMA Dermatol 150, 571-
1613 573.
- 1614 Killingsworth, D.W., Stern, G.A., Driebe, W.T., Knapp, A., Dragon, D.M., 1993. Results of
1615 therapeutic penetrating keratoplasty. Ophthalmology 100, 534-541.
- 1616 Kim, B.M., Osmanovic, S.S., Edward, D.P., 2005. Pyogenic granulomas after silicone punctal
1617 plugs: a clinical and histopathologic study. Am J Ophthalmol 139, 678-684.
- 1618 [Kim, K.M., Shin, Y.T., Kim, H.K., 2012. Effect of autologous platelet-rich plasma on persistent](#)
1619 [corneal epithelial defect after infectious keratitis. Jpn J Ophthalmol 56, 544-50.](#)
- 1620 Kirkness, C.M., Adams, G.G., Dilly, P.N., Lee, J.P., 1988. Botulinum toxin A-induced protective
1621 ptosis in corneal disease. Ophthalmology 95, 473-480.
- 1622 Klein, M., 1943. Contact Lens in Cases of Neuroparalytic Keratitis. Br J Ophthalmol 27, 221-
1623 222.
- 1624 Koizumi, N.J., Inatomi, T.J., Sotozono, C.J., Fullwood, N.J., Quantock, A.J., Kinoshita, S., 2000.
1625 Growth factor mRNA and protein in preserved human amniotic membrane. Curr Eye Res 20,
1626 173-177.
- 1627 Kossendrup, D., Wiederholt, M., Hoffmann, F., 1985. Influence of cyclosporin A,
1628 dexamethasone, and benzalkonium chloride (BAK) on corneal epithelial wound healing in the
1629 rabbit and guinea pig eye. Cornea 4, 177-181.
- 1630 Kruse, F.E., Rohrschneider, K., Volcker, H.E., 1999. Multilayer amniotic membrane
1631 transplantation for reconstruction of deep corneal ulcers. Ophthalmology 106, 1504-1510;
1632 discussion 1511.
- 1633 Kugadas, A., Gadjeva, M., 2016. Impact of Microbiome on Ocular Health. Ocul Surf 14, 342-
1634 349.
- 1635 Labbe, A., Alalwani, H., Van Went, C., Brasnu, E., Georgescu, D., Baudouin, C., 2012. The
1636 relationship between subbasal nerve morphology and corneal sensation in ocular surface disease.
1637 Invest Ophthalmol Vis Sci 53, 4926-4931.
- 1638 Labetoulle, M., Auquier, P., Conrad, H., Crochard, A., Daniloski, M., Bouee, S., El Hasnaoui,
1639 A., Colin, J., 2005. Incidence of herpes simplex virus keratitis in France. Ophthalmology 112,
1640 888-895.

- 1641 Lambiase, A., Manni, L., Bonini, S., Rama, P., Micera, A., Aloe, L., 2000. Nerve growth factor
1642 promotes corneal healing: structural, biochemical, and molecular analyses of rat and human
1643 corneas. *Invest Ophthalmol Vis Sci* 41, 1063-1069.
- 1644 Lambiase, A., Rama, P., Bonini, S., Caprioglio, G., Aloe, L., 1998. Topical treatment with nerve
1645 growth factor for corneal neurotrophic ulcers. *N Engl J Med* 338, 1174-1180.
- 1646 Launay, P.S., Godefroy, D., Khabou, H., Rostene, W., Sahel, J.A., Baudouin, C., Melik
1647 Parsadaniantz, S., Reaux-Le Goazigo, A., 2015. Combined 3DISCO clearing method, retrograde
1648 tracer and ultramicroscopy to map corneal neurons in a whole adult mouse trigeminal ganglion.
1649 *Exp Eye Res* 139, 136-143.
- 1650 LaVail, J.H., Johnson, W.E., Spencer, L.C., 1993. Immunohistochemical identification of
1651 trigeminal ganglion neurons that innervate the mouse cornea: relevance to intercellular spread of
1652 herpes simplex virus. *J Comp Neurol* 327, 133-140.
- 1653 Lee, H.K., Lee, K.S., Kim, H.C., Lee, S.H., Kim, E.K., 2005. Nerve growth factor concentration
1654 and implications in photorefractive keratectomy vs laser in situ keratomileusis. *Am J Ophthalmol*
1655 139, 965-971.
- 1656 [Lee, W.B., Himmel, K., 2006. Corneal ulceration and perforation with ketorolac tromethamine. Cornea 25, 1268.](#)
1657
- 1658 Leon-Feliu, E., Gomez-Ramos, P., Rodriguez-Echandia, E.L., 1978. Endothelial nerve fibres in
1659 the cornea of the frog *Rana ridibunda*. *Experientia* 34, 1352-1353.
- 1660 Li, Z., Burns, A.R., Han, L., Rumbaut, R.E., Smith, C.W., 2011. IL-17 and VEGF are necessary
1661 for efficient corneal nerve regeneration. *Am J Pathol* 178, 1106-1116.
- 1662 Liang, H., Baudouin, C., Daull, P., Garrigue, J.S., Buggage, R., Brignole-Baudouin, F., 2012. In
1663 vitro and in vivo evaluation of a preservative-free cationic emulsion of latanoprost in corneal
1664 wound healing models. *Cornea* 31, 1319-1329.
- 1665 Lim, C.H., Ruskell, G.L., 1978. Corneal nerve access in monkeys. *Albrecht Von Graefes Arch*
1666 *Klin Exp Ophthalmol* 208, 15-23.
- 1667 Lin, X., Xu, B., Sun, Y., Zhong, J., Huang, W., Yuan, J., 2014. Comparison of deep anterior
1668 lamellar keratoplasty and penetrating keratoplasty with respect to postoperative corneal
1669 sensitivity and tear film function. *Graefe's archive for clinical and experimental ophthalmology =*
1670 *Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie* 252, 1779-1787.
- 1671 Liu, D., Sadhan, Y., 2002. Surgical punctal occlusion: a prospective study. *Br J Ophthalmol* 86,
1672 1031-1034.
- 1673 Lockwood, A., Hope-Ross, M., Chell, P., 2006. Neurotrophic keratopathy and diabetes mellitus.
1674 *Eye (London, England)* 20, 837-839.
- 1675 [López-Plandolit, S., Morales, M.C., Freire, V., Etxebarria, J., Durán, J.A., 2010. Plasma rich in](#)
1676 [growth factors as a therapeutic agent for persistent corneal epithelial defects. Cornea 29, 843-8.](#)

- 1677 [Mencucci, R., Paladini, I., Pellegrini-Giampietro, D.E., Menchini, U., Scartabelli, T., 2011. In](#)
 1678 [vitro comparison of the cytotoxic effects of clinically available ophthalmic solutions of](#)
 1679 [fluoroquinolones on human keratocytes. Can J Ophthalmol 46, 513-20.](#)
- 1680 [M'Garrech, M., Rousseau, A., Kaswin, G., Sauer, A., Barreau, E., Bourcier, T., Labetoulle, M.,](#)
 1681 [2013. Impairment of lacrimal secretion in the unaffected fellow eye of patients with recurrent](#)
 1682 [unilateral herpetic keratitis. Ophthalmology 120, 1959-67.](#)
- 1683 Ma'luf, R.N., Awwad, S.T., 2005. Mucous membrane graft versus Gunderson conjunctival flap
 1684 for fitting a scleral shell over a sensitive cornea. *Ophthal Plast Reconstr Surg* 21, 356-358.
- 1685 MacIver, M.B., Tanelian, D.L., 1993. Free nerve ending terminal morphology is fiber type
 1686 specific for A delta and C fibers innervating rabbit corneal epithelium. *J Neurophysiol* 69, 1779-
 1687 1783.
- 1688 Mackie, I.A., 1995. Neuroparalytic keratitis, in: Fraunfelder, F.T., Roy, F.H., Grove, J. (Eds.),
 1689 *Current Ocular Therapy*, 4 ed. W. B. Saunders, Philadelphia, pp. 452-454.
- 1690 Magendie, J., 1824. De la influence de la cinquieme paire nerfts sur la nutrition et les fonctions de
 1691 l'oeil. *Journal of Physiology* 4, 176-182.
- 1692 Mantelli, F., Allegretti, M., Chao, W., Filatori, I., Battigello, P., Vaja, V., Goodman, J.,
 1693 Sinigaglia, F., 2017. Phase I/II randomized, double-masked, vehicle-controlled trial of
 1694 recombinant human nerve growth factor (rhNGF) eye drops in stage 2/3 neurotrophic keratitis
 1695 [abstract]. *Investigative Ophthalmology & Visual Science* 58, 1172.
- 1696 Mantelli, F., Nardella, C., Tiberi, E., Sacchetti, M., Bruscolini, A., Lambiase, A., 2015.
 1697 Congenital Corneal Anesthesia and Neurotrophic Keratitis: Diagnosis and Management. *Biomed*
 1698 *Res Int* 2015, 805876.
- 1699 Marfurt, C.F., Cox, J., Deek, S., Dvorscak, L., 2010. Anatomy of the human corneal innervation.
 1700 *Exp Eye Res* 90, 478-492.
- 1701 Marfurt, C.F., Ellis, L.C., 1993. Immunohistochemical localization of tyrosine hydroxylase in
 1702 corneal nerves. *J Comp Neurol* 336, 517-531.
- 1703 Marfurt, C.F., Jones, M.A., Thrasher, K., 1998. Parasympathetic innervation of the rat cornea.
 1704 *Exp Eye Res* 66, 437-448.
- 1705 Marfurt, C.F., Kingsley, R.E., Echtenkamp, S.E., 1989. Sensory and sympathetic innervation of
 1706 the mammalian cornea. A retrograde tracing study. *Invest Ophthalmol Vis Sci* 30, 461-472.
- 1707 Martone, G., Frezzotti, P., Tosi, G.M., Traversi, C., Mittica, V., Malandrini, A., Pichierri, P.,
 1708 Balestrazzi, A., Motolese, P.A., Motolese, I., Motolese, E., 2009. An in vivo confocal
 1709 microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal
 1710 innervation and morphology. *Am J Ophthalmol* 147, 725-735 e721.
- 1711 Mathers, W.D., 2000. Why the eye becomes dry: a cornea and lacrimal gland feedback model.
 1712 *CLAO J* 26, 159-165.

- 1713 Matsuyama, A., Takatori, S., Sone, Y., Ochi, E., Goda, M., Zamami, Y., Hashikawa-Hobara, N.,
 1714 Kitamura, Y., Kawasaki, H., 2017. Effect of Nerve Growth Factor on Innervation of Perivascular
 1715 Nerves in Neovascultures of Mouse Cornea. *Biol Pharm Bull* 40, 396-401.
- 1716 Mauriello, J.A., Jr., Fiore, P.M., Pokorny, K.S., Cinotti, D.J., 1988. Use of split-thickness dermal
 1717 graft in the surgical treatment of corneal and scleral defects. *Am J Ophthalmol* 105, 244-247.
- 1718 McKemy, D.D., Neuhauser, W.M., Julius, D., 2002. Identification of a cold receptor reveals a
 1719 general role for TRP channels in thermosensation. *Nature* 416, 52-58.
- 1720 Messmer, E.M., Schmid-Tannwald, C., Zapp, D., Kampik, A., 2010. In vivo confocal
 1721 microscopy of corneal small fiber damage in diabetes mellitus. *Graefes Arch Clin Exp*
 1722 *Ophthalmol* 248, 1307-1312.
- 1723 Micera, A., Lambiase, A., Puxeddu, I., Aloe, L., Stampachiacchiere, B., Levi-Schaffer, F.,
 1724 Bonini, S., Bonini, S., 2006. Nerve growth factor effect on human primary fibroblastic-
 1725 keratocytes: possible mechanism during corneal healing. *Exp Eye Res* 83, 747-757.
- 1726 Middlemore, R., 1835. Chapter 3: diseases of the cornea, in: Middlemore, R. (Ed.), *A treatise on*
 1727 *the diseases of the eye and its appendages*, volume 1. Longman, Rees, Orme, Brown, Green, and
 1728 Longman, and James Drake, London, Birmingham.
- 1729 [Mishima, S., 1957. The effects of the denervation and stimulation of the sympathetic and](#)
 1730 [trigeminal nerve on the mitotic rate of the corneal epithelium in the rabbit. *Jpn J Ophthalmol* 1,](#)
 1731 [65-73.](#)
- 1732 Mitra, A., Tsesmetzoglou, E., McElvanney, A., 2007. Corneal deposits and topical ofloxacin--the
 1733 effect of polypharmacy in the management of microbial keratitis. *Eye (Lond)* 21, 410-412.
- 1734 Mohammed, I., Said, D.G., Dua, H.S., 2017. Human antimicrobial peptides in ocular surface
 1735 defense. *Prog Retin Eye Res* 61, 1-22.
- 1736 Morgan, C., DeGroat, W.C., Jannetta, P.J., 1987. Sympathetic innervation of the cornea from the
 1737 superior cervical ganglion. An HRP study in the cat. *J Auton Nerv Syst* 20, 179-183.
- 1738 Morgan, C.W., Nadelhaft, I., de Groat, W.C., 1978. Anatomical localization of corneal afferent
 1739 cells in the trigeminal ganglion. *Neurosurgery* 2, 252-258.
- 1740 Morishige, N., Morita, Y., Yamada, N., Nishida, T., Sonoda, K.H., 2014. Congenital hypoplastic
 1741 trigeminal nerve revealed by manifestation of corneal disorders likely caused by neural factor
 1742 deficiency. *Case reports in ophthalmology* 5, 181-185.
- 1743 Muller, L.J., Marfurt, C.F., Kruse, F., Tervo, T.M., 2003. Corneal nerves: structure, contents and
 1744 function. *Exp Eye Res* 76, 521-542.
- 1745 Muller, L.J., Pels, L., Vrensen, G.F., 1996. Ultrastructural organization of human corneal nerves.
 1746 *Invest Ophthalmol Vis Sci* 37, 476-488.
- 1747 Muller, L.J., Vrensen, G.F., Pels, L., Cardozo, B.N., Willekens, B., 1997. Architecture of human
 1748 corneal nerves. *Invest Ophthalmol Vis Sci* 38, 985-994.

- 1749 Murata, Y., Masuko, S., 2006. Peripheral and central distribution of TRPV1, substance P and
1750 CGRP of rat corneal neurons. *Brain Res* 1085, 87-94.
- 1751 Nagai, N., Murao, T., Okamoto, N., Ito, Y., 2010. Comparison of corneal wound healing rates
1752 after instillation of commercially available latanoprost and travoprost in rat debrided corneal
1753 epithelium. *J Oleo Sci* 59, 135-141.
- 1754 Nakagawa, S., Nishida, T., Kodama, Y., Itoi, M., 1990. Spreading of cultured corneal epithelial
1755 cells on fibronectin and other extracellular matrices. *Cornea* 9, 125-130.
- 1756 Namavari, A., Chaudhary, S., Ozturk, O., Chang, J.H., Yco, L., Sonawane, S., Katam, N.,
1757 Khanolkar, V., Hallak, J., Sarkar, J., Jain, S., 2012. Semaphorin 7a links nerve regeneration and
1758 inflammation in the cornea. *Invest Ophthalmol Vis Sci* 53, 4575-4585.
- 1759 Nubile, M., Dua, H.S., Lanzini, M., Ciancaglini, M., Calienno, R., Said, D.G., Pocobelli, A.,
1760 Mastropasqua, R., Carpineto, P., 2011. In vivo analysis of stromal integration of multilayer
1761 amniotic membrane transplantation in corneal ulcers. *Am J Ophthalmol* 151, 809-822 e801.
- 1762 [Ogut, D., Reel, B., Gonen-Korkmaz, C., Arun, M.Z., Cilaker Micili, S., Ergur, B.U., 2016.](#)
1763 [Doxycycline down-regulates matrix metalloproteinase expression and inhibits NF- \$\kappa\$ B signaling](#)
1764 [in LPS-induced PC3 cells. *Folia Histochem Cytobiol* 54, 171-180.](#)
- 1765 Panda, A., Pushker, N., Bageshwar, L.M., 1999. Lateral tarsorrhaphy: is it preferable to
1766 patching? *Cornea* 18, 299-301.
- 1767 Park, J.H., Kang, S.S., Kim, J.Y., Tchah, H., 2016. Nerve Growth Factor Attenuates Apoptosis
1768 and Inflammation in the Diabetic Cornea. *Invest Ophthalmol Vis Sci* 57, 6767-6775.
- 1769 Parker, A.V., Williams, R.N., Paterson, C.A., 1985. The effect of sodium citrate on the
1770 stimulation of polymorphonuclear leukocytes. *Invest Ophthalmol Vis Sci* 26, 1257-1261.
- 1771 Parra, A., Gonzalez-Gonzalez, O., Gallar, J., Belmonte, C., 2014. Tear fluid hyperosmolality
1772 increases nerve impulse activity of cold thermoreceptor endings of the cornea. *Pain* 155, 1481-
1773 1491.
- 1774 Parra, A., Madrid, R., Echevarria, D., del Olmo, S., Morenilla-Palao, C., Acosta, M.C., Gallar, J.,
1775 Dhaka, A., Viana, F., Belmonte, C., 2010. Ocular surface wetness is regulated by TRPM8-
1776 dependent cold thermoreceptors of the cornea. *Nat Med* 16, 1396-1399.
- 1777 Patel, D.V., McGhee, C.N., 2009. In vivo confocal microscopy of human corneal nerves in
1778 health, in ocular and systemic disease, and following corneal surgery: a review. *Br J Ophthalmol*
1779 93, 853-860.
- 1780 Paton, L., 1926. The Trigeminal and Its Ocular Lesions. *Br J Ophthalmol* 10, 305-342.
- 1781 Pavan-Langston, D., Dohlman, C.H., 2008. Boston keratoprosthesis treatment of herpes zoster
1782 neurotrophic keratopathy. *Ophthalmology* 115, S21-23.

- 1783 Peier, A.M., Reeve, A.J., Andersson, D.A., Moqrich, A., Earley, T.J., Hergarden, A.C., Story,
1784 G.M., Colley, S., Hogenesch, J.B., McIntyre, P., Bevan, S., Patapoutian, A., 2002. A heat-
1785 sensitive TRP channel expressed in keratinocytes. *Science* 296, 2046-2049.
- 1786 Perez, V.L., Pflugfelder, S.C., Zhang, S., Shojaei, A., Haque, R., 2016. Lifitegrast, a Novel
1787 Integrin Antagonist for Treatment of Dry Eye Disease. *Ocul Surf* 14, 207-215.
- 1788 Pflugfelder, S.C., Farley, W., Luo, L., Chen, L.Z., de Paiva, C.S., Olmos, L.C., Li, D.Q., Fini,
1789 M.E., 2005. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier
1790 disruption in experimental dry eye. *Am J Pathol* 166, 61-71.
- 1791 Prabhasawat, P., Tesavibul, N., Komolsuradej, W., 2001. Single and multilayer amniotic
1792 membrane transplantation for persistent corneal epithelial defect with and without stromal
1793 thinning and perforation. *Br J Ophthalmol* 85, 1455-1463.
- 1794 Pushker, N., Dada, T., Vajpayee, R.B., Gupta, V., Aggrawal, T., Titiyal, J.S., 2001. Neurotrophic
1795 keratopathy. *CLAO J* 27, 100-107.
- 1796 Qi, H., Chuang, E.Y., Yoon, K.C., de Paiva, C.S., Shine, H.D., Jones, D.B., Pflugfelder, S.C., Li,
1797 D.Q., 2007. Patterned expression of neurotrophic factors and receptors in human limbal and
1798 corneal regions. *Mol Vis* 13, 1934-1941.
- 1799 Quallo, T., Vastani, N., Horridge, E., Gentry, C., Parra, A., Moss, S., Viana, F., Belmonte, C.,
1800 Andersson, D.A., Bevan, S., 2015. TRPM8 is a neuronal osmosensor that regulates eye blinking
1801 in mice. *Nat Commun* 6, 7150.
- 1802 Rabiolo, A., Woodward, M.A., 2017. Neurotrophic keratitis. American Academy of
1803 Ophthalmology, EyeWiki http://eyewiki.aao.org/NEUROTROPHIC_KERATITIS (accessed 20
1804 November 2017).
- 1805 Rahman, I., Said, D.G., Maharajan, V.S., Dua, H.S., 2009. Amniotic membrane in
1806 ophthalmology: indications and limitations. *Eye (Lond)* 23, 1954-1961.
- 1807 Rauz, S., Saw, V.P., 2010. Serum eye drops, amniotic membrane and limbal epithelial stem
1808 cells--tools in the treatment of ocular surface disease. *Cell Tissue Bank* 11, 13-27.
- 1809 Refojo, M.F., Dohlman, C.H., Ahmad, B., Carroll, J.M., Allen, J.C., 1968. Evaluation of
1810 adhesives for corneal surgery. *Arch Ophthalmol* 80, 645-656.
- 1811 Reid, T.W., Murphy, C.J., Iwahashi, C.K., Foster, B.A., Mannis, M.J., 1993. Stimulation of
1812 epithelial cell growth by the neuropeptide substance P. *J Cell Biochem* 52, 476-485.
- 1813 Reim, M., Overkamping, B., Kuckelkorn, R., 1992. [2 years experiences with Tenon-plasty].
1814 *Ophthalmologie* 89, 524-530.
- 1815 Reynier-Rebuffel, A.M., Mathiau, P., Callebort, J., Dimitriadou, V., Farjaudon, N., Kacem, K.,
1816 Launay, J.M., Seylaz, J., Abineau, P., 1994. Substance P, calcitonin gene-related peptide, and
1817 capsaicin release serotonin from cerebrovascular mast cells. *Am J Physiol* 267, R1421-1429.

- 1818 Rodger, F.C., 1950. The pattern of the corneal innervation in rabbits. *Br J Ophthalmol* 34, 107-
1819 113.
- 1820 Rodriguez-Ares, M.T., Lopez-Valladares, M.J., Tourino, R., Vieites, B., Gude, F., Silva, M.T.,
1821 Couceiro, J., 2009. Effects of lyophilization on human amniotic membrane. *Acta Ophthalmol* 87,
1822 396-403.
- 1823 Rolando, M., Zierhut, M., 2001. The ocular surface and tear film and their dysfunction in dry eye
1824 disease. *Surv Ophthalmol* 45 Suppl 2, S203-210.
- 1825 [Rousseau, A., Nasser, G., Chiquet, C., Barreau, E., Gendron, G., Kaswin, G., M'Garrech, M.,](#)
1826 [Benoudiba, F., Ducreux, D., Labetoulle, M., 2015. Diffusion tensor magnetic resonance imaging](#)
1827 [of trigeminal nerves in relapsing herpetic keratouveitis. *PLoS One* 10, e0122186.](#)
- 1828 Rozsa, A.J., Beuerman, R.W., 1982. Density and organization of free nerve endings in the
1829 corneal epithelium of the rabbit. *Pain* 14, 105-120.
- 1830 Sacchetti, M., Lambiase, A., 2014. Diagnosis and management of neurotrophic keratitis. *Clin*
1831 *Ophthalmol* 8, 571-579.
- 1832 Sacchetti, M., Lambiase, A., 2017. Neurotrophic factors and corneal nerve regeneration. *Neural*
1833 *Regen Res* 12, 1220-1224.
- 1834 Sandinha, T., Zaher, S.S., Roberts, F., Devlin, H.C., Dhillon, B., Ramaesh, K., 2006. Superior
1835 forniceal conjunctival advancement pedicles (SFCAP) in the management of acute and
1836 impending corneal perforations. *Eye (Lond)* 20, 84-89.
- 1837 Sarkar, J., Chaudhary, S., Jassim, S.H., Ozturk, O., Chamon, W., Ganesh, B., Tibrewal, S.,
1838 Gandhi, S., Byun, Y.S., Hallak, J., Mahmud, D.L., Mahmud, N., Rondelli, D., Jain, S., 2013.
1839 CD11b+GR1+ myeloid cells secrete NGF and promote trigeminal ganglion neurite growth:
1840 implications for corneal nerve regeneration. *Invest Ophthalmol Vis Sci* 54, 5920-5936.
- 1841 Sarkar, J., Chaudhary, S., Namavari, A., Ozturk, O., Chang, J.H., Yco, L., Sonawane, S.,
1842 Khanolkar, V., Hallak, J., Jain, S., 2012. Corneal neurotoxicity due to topical benzalkonium
1843 chloride. *Invest Ophthalmol Vis Sci* 53, 1792-1802.
- 1844 [Sekundo, W., Augustin, A.J., Stempel, I., 2002. Topical allopurinol or corticosteroids and](#)
1845 [acetylcysteine in the early treatment of experimental corneal alkali burns: a pilot study. *Eur J*](#)
1846 [Ophthalmol 12, 366-72.](#)
- 1847 Schilimow, A., Wiechens, B., 2016. [Botulinum toxin A induced protective ptosis for the
1848 treatment of recurrent epithelial defects in neurotrophic keratopathy]. *Ophthalmologe*.
- 1849 Schlotzer-Schrehardt, U., Zagorski, Z., Holbach, L.M., Hofmann-Rummelt, C., Naumann, G.O.,
1850 1999. Corneal stromal calcification after topical steroid-phosphate therapy. *Arch Ophthalmol*
1851 117, 1414-1418.

- 1852 Semeraro, F., Forbice, E., Braga, O., Bova, A., Di Salvatore, A., Azzolini, C., 2014. Evaluation
1853 of the efficacy of 50% autologous serum eye drops in different ocular surface pathologies.
1854 *Biomed Res Int* 2014, 826970.
- 1855 Seyed-Razavi, Y., Chinnery, H.R., McMenamin, P.G., 2014. A novel association between
1856 resident tissue macrophages and nerves in the peripheral stroma of the murine cornea. *Invest*
1857 *Ophthalmol Vis Sci* 55, 1313-1320.
- 1858 Sharma, A., Kaur, R., Kumar, S., Gupta, P., Pandav, S., Patnaik, B., Gupta, A., 2003. Fibrin glue
1859 versus N-butyl-2-cyanoacrylate in corneal perforations. *Ophthalmology* 110, 291-298.
- 1860 Sharma, C., Velpandian, T., Baskar Singh, S., Ranjan Biswas, N., Bihari Vajpayee, R., Ghose,
1861 S., 2011. Effect of fluoroquinolones on the expression of matrix metalloproteinase in debrided
1862 cornea of rats. *Toxicol Mech Methods* 21, 6-12.
- 1863 Sinigaglia, F., NGF Study Group, 2014. Phase I/II Dose-Ranging, Randomized Clinical Trial of
1864 Recombinant Human Nerve Growth Factor in the Treatment of Neurotrophic Keratitis:
1865 Preliminary Results (abstract). *Investigative Ophthalmology & Visual Science* 55, ARVO E-
1866 Abstract 4690.
- 1867 [Soni, N.G., Jeng, B.H., 2016. Blood-derived topical therapy for ocular surface diseases. *Br J*](#)
1868 [Ophthalmol](#) 100, 22-7.
- 1869 Soong, H.K., Farjo, A.A., Katz, D., Meyer, R.F., Sugar, A., 2000. Lamellar corneal patch grafts
1870 in the management of corneal melting. *Cornea* 19, 126-134.
- 1871 Stapleton, F., Marfurt, C., Golebiowski, B., Rosenblatt, M., Bereiter, D., Begley, C., Dartt, D.,
1872 Gallar, J., Belmonte, C., Hamrah, P., Willcox, M., Discomfort, T.I.W.o.C.L., 2013. The TFOS
1873 International Workshop on Contact Lens Discomfort: report of the subcommittee on
1874 neurobiology. *Invest Ophthalmol Vis Sci* 54, TFOS71-97.
- 1875 Stepp, M.A., Tadvalkar, G., Hakh, R., Pal-Ghosh, S., 2017. Corneal epithelial cells function as
1876 surrogate Schwann cells for their sensory nerves. *Glia* 65, 851-863.
- 1877 Stern, M.E., Beuerman, R.W., Fox, R.I., Gao, J., Mircheff, A.K., Pflugfelder, S.C., 1998. The
1878 pathology of dry eye: the interaction between the ocular surface and lacrimal glands. *Cornea* 17,
1879 584-589.
- 1880 [Stern, M.E., Schaumburg, C.S., Pflugfelder, S.C., 2013. Dry eye as a mucosal autoimmune](#)
1881 [disease. *Int Rev Immunol* 32, 19-41.](#)
- 1882 Straub, R.H., 2014. TRPV1, TRPA1, and TRPM8 channels in inflammation, energy redirection,
1883 and water retention: role in chronic inflammatory diseases with an evolutionary perspective. *J*
1884 *Mol Med (Berl)* 92, 925-937.
- 1885 Sugita, J., Yokoi, N., Fullwood, N.J., Quantock, A.J., Takada, Y., Nakamura, Y., Kinoshita, S.,
1886 2001. The detection of bacteria and bacterial biofilms in punctal plug holes. *Cornea* 20, 362-365.

- 1887 Sugiura, S., Yamaga, C., 1968. [Studies on the adrenergic nerve of the cornea]. *Nippon Ganka*
1888 *Gakkai Zasshi* 72, 872-879.
- 1889 Suri, K., Kosker, M., Raber, I.M., Hammersmith, K.M., Nagra, P.K., Ayres, B.D., Halfpenny,
1890 C.P., Rapuano, C.J., 2013. Sutureless amniotic membrane ProKera for ocular surface disorders:
1891 short-term results. *Eye Contact Lens* 39, 341-347.
- 1892 Tai, M.C., Cosar, C.B., Cohen, E.J., Rapuano, C.J., Laibson, P.R., 2002. The clinical efficacy of
1893 silicone punctal plug therapy. *Cornea* 21, 135-139.
- 1894 Takamatsu, H., Kumanogoh, A., 2012. Diverse roles for semaphorin-plexin signaling in the
1895 immune system. *Trends Immunol* 33, 127-135.
- 1896 Tanelian, D.L., 1991. Cholinergic activation of a population of corneal afferent nerves. *Exp*
1897 *Brain Res* 86, 414-420.
- 1898 ten Tusscher, M.P., Klooster, J., Vrensen, G.F., 1988. The innervation of the rabbit's anterior eye
1899 segment: a retrograde tracing study. *Exp Eye Res* 46, 717-730.
- 1900 Tervo, T., Joo, F., Huikuri, K.T., Toth, I., Palkama, A., 1979. Fine structure of sensory nerves in
1901 the rat cornea: an experimental nerve degeneration study. *Pain* 6, 57-70.
- 1902 Terzis, J.K., Dryer, M.M., Bodner, B.I., 2009. Corneal neurotization: a novel solution to
1903 neurotrophic keratopathy. *Plast Reconstr Surg* 123, 112-120.
- 1904 Teson, M., Calonge, M., Fernandez, I., Stern, M.E., Gonzalez-Garcia, M.J., 2012.
1905 Characterization by Belmonte's gas esthesiometer of mechanical, chemical, and thermal corneal
1906 sensitivity thresholds in a normal population. *Invest Ophthalmol Vis Sci* 53, 3154-3160.
- 1907 Tinley, C.G., Gray, R.H., 2009. Routine, single session, indirect laser for proliferative diabetic
1908 retinopathy. *Eye (London, England)* 23, 1819-1823.
- 1909 Toivanen, M., Tervo, T., Partanen, M., Vannas, A., Hervonen, A., 1987. Histochemical
1910 demonstration of adrenergic nerves in the stroma of human cornea. *Invest Ophthalmol Vis Sci*
1911 28, 398-400.
- 1912 Tong, L., Beuerman, R., Simonyi, S., Hollander, D.A., Stern, M.E., 2016. Effects of Punctal
1913 Occlusion on Clinical Signs and Symptoms and on Tear Cytokine Levels in Patients with Dry
1914 Eye. *Ocul Surf* 14, 233-241.
- 1915 Tran, M.T., Ritchie, M.H., Lausch, R.N., Oakes, J.E., 2000. Calcitonin gene-related peptide
1916 induces IL-8 synthesis in human corneal epithelial cells. *J Immunol* 164, 4307-4312.
- 1917 Tseng, S.C., Espana, E.M., Kawakita, T., Di Pascuale, M.A., Li, W., He, H., Liu, T.S., Cho,
1918 T.H., Gao, Y.Y., Yeh, L.K., Liu, C.Y., 2004. How does amniotic membrane work? *Ocul Surf* 2,
1919 177-187.
- 1920 Tuisku, I.S., Konttinen, Y.T., Konttinen, L.M., Tervo, T.M., 2008. Alterations in corneal
1921 sensitivity and nerve morphology in patients with primary Sjogren's syndrome. *Exp Eye Res* 86,
1922 879-885.

- 1923 Tuli, S.S., Schultz, G.S., Downer, D.M., 2007. Science and strategy for preventing and managing
1924 corneal ulceration. *Ocul Surf* 5, 23-39.
- 1925 Turkoglu, E., Celik, E., Alagoz, G., 2014. A comparison of the efficacy of autologous serum eye
1926 drops with amniotic membrane transplantation in neurotrophic keratitis. *Semin Ophthalmol* 29,
1927 119-126.
- 1928 Vanathi, M., Sharma, N., Titiyal, J.S., Tandon, R., Vajpayee, R.B., 2002. Tectonic grafts for
1929 corneal thinning and perforations. *Cornea* 21, 792-797.
- 1930 Vasseneix, C., Toubeau, D., Brasseur, G., Muraine, M., 2006. [Surgical management of
1931 nontraumatic corneal perforations: an 8-year retrospective study]. *J Fr Ophtalmol* 29, 751-762.
- 1932 [Walter, K., Tyler, M.E., 2006. Severe corneal toxicity after topical fluoroquinolone therapy:
1933 report of two cases. *Cornea* 25, 855-7.](#)
- 1934 Wasilewski, D., Mello, G.H., Moreira, H., 2013. Impact of collagen crosslinking on corneal
1935 sensitivity in keratoconus patients. *Cornea* 32, 899-902.
- 1936 Wells, J.R., Michelson, M.A., 2008. Diagnosing and Treating Neurotrophic Keratopathy, *EyeNet*
1937 Magazine. American Academy of Ophthalmology,
1938 <https://www.aaopt.org/eyenet/article/diagnosing-treating-neurotrophic-keratopathy> (accessed 20
1939 November 2017).
- 1940 Whitear, M., 1960. An electron microscope study of the cornea in mice, with special reference to
1941 the innervation. *J Anat* 94, 387-409.
- 1942 Wilson, S.E., Ambrosio, R., 2001. Laser in situ keratomileusis-induced neurotrophic
1943 epitheliopathy. *Am J Ophthalmol* 132, 405-406.
- 1944 Wolter, J.R., 1957. Innervation of the corneal endothelium of the eye of the rabbit. *AMA Arch*
1945 *Ophthalmol* 58, 246-250.
- 1946 Wolter, J.R., 1964. Hyper-Regeneration of Corneal Nerves in Bullous Keratopathy. *Am J*
1947 *Ophthalmol* 58, 31-38.
- 1948 Wolter, J.R., 1966. Hyper-regeneration of corneal nerves in a scarred transplant. *Am J*
1949 *Ophthalmol* 61, 880-885.
- 1950 Yamada, N., Matsuda, R., Morishige, N., Yanai, R., Chikama, T.I., Nishida, T., Ishimitsu, T.,
1951 Kamiya, A., 2008. Open clinical study of eye-drops containing tetrapeptides derived from
1952 substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects
1953 associated with neurotrophic keratopathy. *Br J Ophthalmol* 92, 896-900.
- 1954 [Yamaguchi, T., Hamrah, P., Shimazaki, J., 2016. Bilateral alterations in corneal nerves,
1955 dendritic cells, and tear cytokine levels in ocular surface disease. *Cornea*, 35 Suppl 1, S65-S70.](#)
- 1956 [Yamaguchi, T., Turhan, A., Harris, D.L., Hu, K., von Andrian, H.P.U., Hamrah, P., 2013.
1957 Bilateral Nerve Alterations in a Unilateral Experimental Neurotrophic Keratopathy Model: A
1958 Lateral Conjunctival Approach for Trigeminal Axotomy. *PLoS One* 14, e70908.](#)

- 1959 Yamazaki, N., Kobayashi, A., Yokogawa, H., Ishibashi, Y., Oikawa, Y., Tokoro, M., Sugiyama,
1960 K., 2014. In vivo imaging of radial keratoneuritis in patients with Acanthamoeba keratitis by
1961 anterior-segment optical coherence tomography. *Ophthalmology* 121, 2153-2158.
- 1962 [Yoon, K.C., Heo, H., Jeong, I.Y., Park, Y.G., 2005. Therapeutic effect of umbilical cord serum](#)
1963 [eyedrops for persistent corneal epithelial defect. *Korean J Ophthalmol* 19,174-8.](#)
- 1964 [Yoon, K.C., You, I.C., Im, S.K., Jeong, T.S., Park, Y.G., Choi, J., 2007. Application of umbilical](#)
1965 [cord serum eyedrops for the treatment of neurotrophic keratitis. *Ophthalmology* 114, 1637-42.](#)
- 1966 You, L., Kruse, F.E., Volcker, H.E., 2000. Neurotrophic factors in the human cornea. *Invest*
1967 *Ophthalmol Vis Sci* 41, 692-702.
- 1968 Yun, H., Lathrop, K.L., Hendricks, R.L., 2016. A Central Role for Sympathetic Nerves in Herpes
1969 Stromal Keratitis in Mice. *Invest Ophthalmol Vis Sci* 57, 1749-1756.
- 1970 Zander, E., Weddell, G., 1951. Observations on the innervation of the cornea. *J Anat* 85, 68-99.
- 1971 Zhang, M., Chen, J., Luo, L., Xiao, Q., Sun, M., Liu, Z., 2005. Altered corneal nerves in aqueous
1972 tear deficiency viewed by in vivo confocal microscopy. *Cornea* 24, 818-824.
- 1973 Zieske, J.D., Gipson, I.K., 1986. Protein synthesis during corneal epithelial wound healing.
1974 *Invest Ophthalmol Vis Sci* 27, 1-7.
- 1975

1976 15. Legends for Figures

1977

1978 **Fig. 1.** [Diagram illustrating the afferent sensory pathway from the cornea and conjunctiva to the](#)
1979 [trigeminal ganglion and the efferent sympathetic and parasympathetic nerve pathways. Adapted](#)
1980 [and modified from Stern 2013.](#)

1981

1982 **Fig. 2.** Effect of benzalkonium chloride (BAK) on cultured corneal epithelial cells. H0 (hour
1983 zero) the vertical gap created by the ‘scratch’ in a confluent layer of corneal epithelial cells is
1984 visible. H8 (hour 8) the gap is fully closed to establish a confluent sheet again compared to the
1985 BAK group where the defect persists.

1986

1987 | **Fig. 23.** Sequence of events leading to epithelial disturbance, epithelial loss and stromal lysis as
 1988 neurotrophic keratopathy progresses through different stages/grades of severity.

1989

1990 | **Fig. 34.** Grades/stages of neurotrophic keratopathy (NK). (a) Slit lamp broad beam illumination
 1991 showing central, confluent punctate lesions giving the central cornea a dull lack-lustre
 1992 appearance following photorefractive keratectomy (ocular surface syndrome) (OSN). (b) The
 1993 same cornea stained with fluorescein showing that most of the lesions take up stain highlighting
 1994 the epitheliopathy. (c) OSN following laser in-situ keratomileusis. Fluorescein stain of the cornea
 1995 shows coarse, centrally located, almost confluent 'keratitis'. (a – c represent grade/stage 1 NK).
 1996 (d) The central cornea shows a diffuse haze with a large epithelial defect. (e) The central cornea
 1997 is hazy with an epithelial defect with superficial and deep stromal vessels. (f) There is a large
 1998 corneal epithelial defect with a relatively clear stroma. Images d-f represent grade/stage 2 NK.
 1999 The white, rolled margins of the defects is a typical sign of a non-healing epithelial defect. (g)
 2000 Slit view showing stromal melting to mid depth in a case of herpes zoster keratitis. (h) Deep
 2001 stromal ulceration in a child with congenital anaesthetic cornea. (i) A large corneal ulcer in a
 2002 case of treated acanthamoeba keratitis. Inset illustrated the stromal roughening, over which the
 2003 epithelium did not migrate. Note the absence of corneal vascularization. Images g to i represent
 2004 grade/stage 3 NK.

2005

2006 | **Fig. 54.** Complications of neurotrophic keratopathy (NK). (a) Three months following a
 2007 chemical burn the eye shows limbal ischaemia in the inferior half with a large hypopyon. (b) The
 2008 same eye as in (a) stained with fluorescein. A large non healing epithelial defect is seen. Corneal

sensation was absent in the lower half. (c) NK with superadded bacterial infection, stromal melting and ectasia. (d) Same eye as in (c) showing that the area of epithelial defect, stained with fluorescein, corresponds to the stromal involvement. (e) NK in a penetrating corneal graft in an aphakic eye, showing a 'silent' central perforation with prolapse of the vitreous. (f) NK with Descemetocoele and perforation showing aqueous leakage (Sidel positive). The corneas in (e) and (f) developed perforation in the absence of infection.

Fig. 56. Right eye of a patient with mild/stage 1 neurotrophic keratopathy (NK). (a) The lower half of the cornea shows multiple, almost confluent, punctate erosions stained with fluorescein. The upper half has a normal tear film. Inset shows the white appearance of the epitheliopathy. Cochet-Bonnet aesthesiometry measured 60mm in the upper half and 15mm in the lower half. (b) Higher magnification broad beam slit lamp illumination shows the white lesion on the right hand side of the beam and 'vesicular' appearance or intra-epithelial microcysts on the left side of the beam. Intraepithelial vesicular lesions are part of the epitheliopathy of NK. Superficial lesions rupture and stain with fluorescein.

Fig. 67. Left eye of the same patient as in figure 5. (a) The patient underwent penetrating keratoplasty for herpes simplex virus keratitis related scars. Post-operatively she presented with moderate/grade 2 neurotrophic keratopathy (NK). An epithelial defect with underlying and surrounding stromal haze is seen. (b) On fluorescein staining the ulcer is delineated. The surrounding epithelium shows coarse punctate keratitis. (c) NK progressed to severe grade/ stage 3. Various treatment options were tried including an amniotic membrane patch. The ulcer healed but left a scarred vascularized cornea, shown a year later. (d) Two years post-graft the corneal graft has failed with a dense scar and further vascularization. Corneal sensations were absent.

2032 The case illustrates that with conventional therapeutic interventions, ‘successful’ healing of
 2033 severe NK can be associated with severely compromised vision.

2034

2035 | **Fig. 78.** Progression of neurotropic keratopathy (NK). (a) Following successful treatment of
 2036 acanthamoeba keratitis, there was marked reduction of corneal sensation (Cochet-Bonnet 5 mm)
 2037 with moderate/stage 2 NK. (b) NK progressed with stromal lysis and (c) perforation, despite
 2038 treatment.

2039

2040 | **Fig. 89.** Diagnostic algorithm for neurotrophic keratopathy.

2041

2042 | **Fig. 910.** Testing corneal sensation. (a) Testing corneal sensation with a wisp of cotton. This is a
 2043 qualitative test and easy to perform at the bedside. However, the cotton is usually not sterile or
 2044 even if so, is drawn into a thin wisp with ‘un-sterile’ fingers. (b) testing corneal sensation with
 2045 the Cochet-Bonnet aesthesiometer. The fine nylon thread is sterilised by wiping it with an
 2046 alcohol swab. (c) The set up of the Belmonte aesthesiometer. A controlled jet of air is targeted on
 2047 the cornea and the patient’s response is both observed and interrogated.

2048

2049 | **Fig. 1011.** (a) A case of severe neurotrophic keratopathy (NK) examined by in-vivo confocal
 2050 microscopy (IVCM). (b) IVCM of the ulcerated area appears as a dark hypo-reflective patch
 2051 with scattered fine hyper-reflective speck (possible inflammatory cells/reactive keratocytes) and
 2052 surrounded by the hyper-reflective epithelial cells of the ulcer margin. (c) A large stromal nerve

is seen as a hyper-reflective line in the deep stroma of the peripheral non-ulcerated area. (d) The stroma in the vicinity of the ulcer shows disorganization with reactive keratocytes. (e) The epithelium in the vicinity of the ulcer shows altered morphology and absence of the sub-basal plexus.

Fig. 4412. Anterior segment optical coherence tomography (ASOCT) in neurotrophic keratopathy (NK). (a) Severe NK with stromal melting. (b) ASOCT of the cornea illustrating the depth of the ulcer and its contour. The facet is filled with instilled tear drops. The density of the stroma (yellow red colour) is greater in the stroma around the ulcer. Anterior bowing of the posterior corneal layer can be appreciated indicating the start of a Descemetocoele.

Fig. 4213. Response to treatment with recombinant nerve growth factor (NGF) eye drops. (a) Moderate grade/stage 2 neurotrophic keratopathy. (b) & (c) complete closure of the epithelial defect occurred with NGF drops instilled six times a day for a few weeks.

Fig. 4314. Beneficial effect of botulinum toxin induced ptosis in neurotrophic keratopathy (NK). (a) The cornea shows a large area of moderate grade/stage 2 NK. (b) Complete ptosis of the upper lid is achieved with botulinum toxin injection. (c) Healing of NK at 2 weeks and (d) complete healing at 4 weeks.

Fig. 4415. Tarsorrhaphy, arguably the most effective surgical intervention in neurotrophic keratopathy (NK). (a) A cornea with unilateral chemical burn was treated with autologous limbal

transplant. A persistent epithelial defect is seen (NK moderate grade/stage 2). (b) A lateral tarsorrhaphy was performed. (c) Complete healing of NK is seen. (d), (e) and (f) are corresponding fluorescein stained images showing the original epithelial defect, reduction in size of the defect and complete healing respectively.

2078

Fig. 4516. Amniotic membrane transplant (AMT) in management of severe neurotrophic keratopathy (NK). (a) Severe (stage 3) NK following trabeculectomy operation, which did not respond to medical management. The central stroma is necrotic and surrounded by a gutter of stromal lysis. (b) The ‘gutter’ is epithelialized but no epithelium has grown over the central necrotic stroma (fluorescein stained). (c) An AMT (Omnigen 500 graft) with a running 10 ‘O’ nylon suture was used to cover the defect after dissecting off the necrotic stroma.

2085

Fig. 4617. Corneal perforation managed by application of cyanoacrylate tissue adhesive. (a) A case of bacterial corneal ulcer, medically treated with intensive antibiotics. The ulcer was rendered sterile but remained as a persistent defect with reduced sensation, progressing to perforation at two sites. Multiple patches of cyanoacrylate glue were required to seal the perforations. (c) Two months later, the glue has been dislodged revealing a scarred and vascularized cornea. The perforations have sealed and the anterior chamber is formed.

2092

2093

Table 1. Terms used to describe corneal nerves related pathology.

Non-Healing corneal epithelial defects
--

Persistent corneal epithelial defects
Slow-healing corneal epithelial defects
Neuropathic keratitis (epithelial defects)
Neurotrophic keratitis/keratopathy
Neuroparalytic keratitis/keratopathy
Ocular surface syndrome and Neurotrophic epitheliopathy post-Lasik

Table 2. Common causes of ocular surface nerve damage that may lead to neurotrophic keratopathy

<ul style="list-style-type: none"> • <i>Genetic</i> (Morishige et al., 2014) <ul style="list-style-type: none"> ○ Riley–Day syndrome (familial dysautonomia) ○ Goldenhar–Gorlin syndrome ○ Mobius syndrome ○ Familial corneal hypoaesthesia
<ul style="list-style-type: none"> • <i>Systemic</i> <ul style="list-style-type: none"> ○ Diabetes mellitus. (Lockwood et al., 2006)

○ Leprosy
○ Vitamin A deficiency
○ Amyloidosis
○ Multiple sclerosis
• <i>Central nervous system</i>
○ Neoplasm
○ Aneurysms
○ Stroke
○ Degenerative disorders of the central nervous system (Alzheimers, Parkinsons)
○ Post neurosurgical procedures
○ For acoustic neuroma
○ For trigeminal neuralgia
○ Other surgical injury to the trigeminal nerve
• <i>Ocular</i>
○ Post-herpes infections (herpes simplex and herpes zoster)
○ <u>Other infections e.g acanthamoeba with nerve damage related to keratoneuritis</u>
○ Chemical and physical burns
○ Abuse of topical anaesthetics
○ Drug toxicity (timolol, betaxolol, diclofenac sodium, sulphacetamide 30%)
○ Chronic ocular surface injury or inflammation
○ Ocular surgery <ul style="list-style-type: none"> ■ Alterations of cornea sensitivity have been observed after cataract surgery even if no frank NK has been reported. ■ Laser in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK) have been have been described as possible causes of NK even if in most cases transient. (Wilson and Ambrosio, 2001) ■ Penetrating keratoplasty (PK) and deep anterior lamellar keratoplasty (DALK) can cause some degree of corneal denervation. up to 12 months after surgery ,[6] but NK is not very frequent in after this kind of surgery. (Lin et al., 2014) ■ Collagen crosslinking for keratoconus.[8]also show a frequently transient reduction of corneal sensitivity (Wasilewski et al., 2013) ■ Development or worsening of NK has been frequently associated with vitrectomy for retinal detachment and photocoagulation to treat diabetic retinopathy (Banerjee et al., 2014) ■ Postsurgical or laser treatment (trauma of ciliary nerves) Routine, single session, indirect laser for proliferative diabetic retinopathy has also been reported as a possible cause of NK. (Tinley and Gray, 2009)
○ Contact lens wear
○ Orbital neoplasia

- Corneal dystrophies (lattice, granular)

Adapted from author's own publication. (Bonini et al., 2003)

Table 3: Step-ladder approach to management of NK

Clinical grade	Therapeutic Options	Intervention Aim
Mild (stage 1)	<ul style="list-style-type: none"> Discontinuation of all topical medications especially if containing preservatives. Evaluation of side effects of systemic therapies such as neuroleptic, antipsychotic, and antihistamine drugs. Treat concurrent ocular surface problems, especially infection of ocular surface / lacrimal passage. Anti-inflammatory therapy if inflammation present (non-steroidal anti-inflammatory drugs can be toxic) Tear substitution / Administration of topical preservative-free lubricants. Punctal occlusion. Correction of lid abnormalities. Debridement of sick epithelium. 	<ul style="list-style-type: none"> Improve epithelial quality and transparency. Stabilise epithelium and avoid epithelial breakdown. Prevent progression to Moderate grade (stage 2, persistent epithelial defect).
Moderate (stage 2)	<p><i>As per Stage 1 and:</i></p> <ul style="list-style-type: none"> Prophylactic topical preservative-free antibiotics. Prevention of melting with Citrate / tetracycline / macrolides (if stromal involvement is threatened) Recombinant Human (rh)NGF (Cenegermin / Oxervate). Q10 co-enzyme. Cacicol 20 / RGTA. Serum eye drops, platelet-rich plasma Corneal or scleral therapeutic contact lenses. Non-surgical Eyelid closure. Debridement of 'rolled' edges of epithelial defect. Tarsorrhaphy. Amniotic membrane transplantation usually single layer as patch. Conjunctival flaps. 	<ul style="list-style-type: none"> Promote epithelial healing Prevent the occurrence/recurrence of the epithelial breakdown Prevent progression to Severe grade (stage 3, stromal lysis)
<i>As per Stage 2 and:</i>		

Severe
(stage 3)

- rhNGF and RGTA are likely to be of particular help.
- Amniotic membrane, multilayer, usually as graft. Can be combined with tarsorrhaphy.
- Corneal grafts (tectonic, lamellar or full thickness).
- Promote corneal healing.
- Prevent further corneal stromal lysis and perforation.

In the event of perforation

- Cyanoacrylate tissue adhesive with therapeutic contact lens.
 - Fibrin glue.
 - Amniotic membrane graft or corneal grafts.
-

For each grade, all interventions listed may not be required.

Table 4: Summary of ocular lubricants

Viscosity	Compound
Low	Hypromellose 0.3%
	Polyvinyl alcohol
Thin-medium	Carbomers
	Carmellose 0.5-1.0%
Thick-medium	Hyaluronates (0.1-0.4%)
	Trehalose 3%
High	Paraffin/white petroleum
	Retinoic acid ointment

Table 5. Shows efficacy of cenegermin 20 µg/ml compared to vehicle in the two studies.

		Study NGF0212		Study NGF 0214	
Results after 4 and 8 weeks of treatment		Week 4	Week 8	Week 4	Week 8
Complete corneal healing rate	OXERVATE	58.0 %	74.0 %	56.5 %	69.6 %
	vehicle	19.6 %	43.1 %	37.5 %	29.2 %
	(p value)	(0.001)	(0.002)	(0.191)	(0.006)

Formatted: Line spacing: Multiple
1.08 li

Formatted: Line spacing: Multiple
1.08 li, Suppress line numbers

Formatted: Line spacing: Multiple
1.08 li, Suppress line numbers

Formatted: Line spacing: Multiple
1.08 li, Suppress line numbers

Formatted: Line spacing: Multiple
1.08 li